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ABSTRACT
EXPRESSION AND FUNCTION OF ZEBRA:
THE EPSTEIN-BARR VIRAL REPLICATION ACTIVATOR
Naomi Taylor
Yale University
1991

Epstein-Barr virus (EBV) encodes a protein, ZEBRA,
which enables the virus to switch from a latent to a lytic
life cycle.

ZEBRA expression was studied in lymphoid cells

harboring either standard virus or a mixture of standard and
defective viruses.

ZEBRA protein could not be detected in

cells latently infected with standard EBV but was
constitutively expressed in cells containing both defective
and standard EBV genomes.

Experiments indicated that

regulation of transcription of the ZEBRA gene (BZLFl) is a
pivotal event in the control of EBV replication.

ZEBRA

specific BZLFl transcripts were spontaneously expressed in
cells harboring defective virus but were only synthesized by
the latent virus after chemical induction.

BZLFl

transcription was sensitive to inhibition of protein
synthesis but not to inhibition of lytic viral DNA
synthesis.

This suggests that ZEBRA is an early replicative

protein whose expression is dependent on the synthesis of a
viral or cellular factor.
The basic domain of the ZEBRA protein is homologous to
the Fos/Jun oncogene family and shares their ability to bind
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the canonical AP-1 site (TGAGTCA).

However, ZEBRA does not

contain a leucine zipper domain; a motif necessary for DNA
binding of Fos/Jun proteins.

Additionally, ZEBRA binds to

sites which deviate from the AP-1 consensus sequence.

Thus,

it was of interest to study the DNA binding properties of
the ZEBRA protein.
Deletional mutagenesis of the BZLFl cDNA indicated that
amino acids 172-227, representing the basic and putative
dimerization domains, were required for specific binding to
AP-1 and divergent sites.

Mutagenesis of three basic amino

acids, which are conserved in Fos, abrogated ZEBRA binding
to all target sequences.

Additionally, ZEBRA was determined

to bind DNA as a homodimer.
DNA binding studies of ZEBRA and a Fos-GCN4 chimera
indicated that although these proteins have homology in
their basic DNA binding domains, they have different cognate
binding specificities.

The autoregulated BZLFl promoter

contains three divergent AP-1 sequences; Fos-GCN4 uniquely
recognized one of the sites while ZEBRA bound only the other
two sequences.

Additionally, ZEBRA, but not Fos, was found

to be phosphorylated by casein kinase II in-vitro.

This

phosphorylation abrogated ZEBRA binding to all of its target
DNA sequences. Regulation of ZEBRA'S DNA binding activity
may be required for the progression of the EBV replicative
cycle.
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CHAPTER I
INTRODUCTION

Epstein-Barr virus (EBV) is a human lymphotropic
herpesvirus which was first identified in cultured Burkitt's
lymphoma cells (BL) (Epstein et al., 1964).

The virus has

also been linked to nasopharyngeal carcinoma (NPC), a tumor
commonly found in southern China (deSchryver et al., 1969).
Although EBV has not been proven to be the etiologic agent
in either of these malignancies, it has been shown to
produce a benign lymphoproliferative disease, infectious
mononucleosis (Henle et al., 1968, Niedeman et al., 1968).
This lymphoproliferation can become fatal in patients who
have inherited or acguired immunodeficiencies (Hanto et al.,
1981, Purtillo, 1981).

Additionally, infection with EBV in-

vitro was found to result in the immortalization of fresh
neonatal lymphocytes (Henle et al., 1968, Pope et al, 1968,
Miller et al., 1969).
Lymphoid cells immortalized with the Epstein-Barr virus
generally maintain the virus in the latent state.

These

cells can harbor up to 800 EBV genomes as unintegrated
extra-chromosomal plasmids or episomes (Sugden et al.,
1979).

The virus is maintained in a tightly latent state in

both Burkitt's lymphoma and nasopharyngeal carcinoma (RaabTraub et al., 1983, Rowe et al., 1986, Tugwood et al.,
1987).

Conversely, EBV was found to be highly replicated in
1
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oral hairy leukoplakia (OHL), an AIDS associated lesion
(Greenspan et al., 1985).

OHL is associated with chronic

productive EBV infection in the epithelial cells of the
tongue.

In contrast with BL and NPC cells, replicating

virus and mature EBV virions are found in OHL lesions
(Greenspan et al., 1985).

Thus, Epstein-Barr virus is

associated with the pathogenesis of disease in both its
latent and lytic states.

This study focuses on the role of

the EB viral protein, ZEBRA, which regulates the switch
between the latent and lytic viral life cycles.
The Epstein-Barr viral genome is a double stranded DNA
molecule of approximately 172,000 base pairs (bp)

(Pritchett

et al., 1975, Hayward and Kieff, 1977, Baer et al., 1984).
Whereas the EBV genome is linear in virions, it exists as a
covalently closed circular plasmid in latently infected
cells (Lindahl et al., 1976, Pritchett et al., 1975).
Circularization occurs at the terminal repeats; 4-12 direct
reiterations of a 500 bp sequence (Given et al., 1979,
Kintner and Sugden, 1979).

Only rarely have integrated

copies of the EBV genome been identified (Henderson et al.,
1983, Matsuo et al., 1984).
EBV infection is restricted to cells expressing the 14 0
Kd C3d complement receptor which has been designated CR2 or
CD21 (Fingeroth et al., 1984, Frade et al., 1985).

Resting

B lymphocytes as well as epithelial cells of the orophaynx
and cervix and some T cell lines express this receptor on
2
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the cell surface (Robinson et al., 1979, Sixbey et al.,
1986, 1987, Stocco et al., 1988).

Binding of the virus is

mediated through the interaction of CR2 and the EBV
glycoprotein, gp 350 (Hoffman et al., 1980).
EBV infection results in a continuous proliferation of
lymphocytes in-vitro, a process termed immortalization.
Cells immortalized by EBV maintain the virus in the latent
state and express only a few virally encoded genes.

Ten

viral gene products have been identified in these cells
including six EB nuclear antigens (EBNAs, labeled EBNA-1 to
EBNA-6), the latent membrane protein (LMP), two small RNAs
(EBER-1 and EBER-2), and the terminal protein (TP) (reviewed
in Miller, 1990).

Although the process of immortalization

is not well understood, the EBNA-2 protein appears to play a
critical role.

EB viral strains which contain deletions in

this region (such as P3-HR-1) are immortalization
incompetent (Bornkamm et al., 1982, Rabson et al., 1982).
Replication of the latent EBV genome in synchrony with
host cell DNA synthesis results in a stable partitioning of
the virus to daughter cells (Adams, 1987, Hampar et al.,
1974) .

This process requires the interaction of the EBNA-1

protein with a 1.8 Kb subfragment of the EBV genome termed
oriP, origin of plasmid replication (Yates et al., 1984).
EBNA-1 binds a 30 bp repeated sequence located within oriP
(Rawlins et al., 1985).
Latent EB virus can be activated, in-vitro, by a
3
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variety of external stimuli such as butyrate, phorbol esters
and serum factors (Bauer et al., 1985, Luka et al., 1979,
zur Hausen et al., 1979).

At least 55 distinct viral genes

are expressed during the replicative cycle (Hummel and
Kieff, 1982, Weigel et al., 1983).

Early antigens (EA) as

well as late gene products such as the viral capsid antigen
(VCA) (a protein sensitive to inhibition of viral DNA
synthesis)
induction.

(Summers and Klein, 1976) are expressed following
Raji cells, which do not replicate viral DNA

from the lytic origin, can produce early but not late
antigens (Goodman et al., 1978).
Replicative antigens are spontaneously expressed at a
low level in some "lytic producer" strains of EBV.

The non

immortalizing HR-1 strain is a lytic virus as defined by its
ability to induce EA in superinfected latent Raji cells
(Henle et al., 1970).

The HR-1 cell line was derived as a

subclone of the Burkitt lymphoma cell line, Jijoye (Hinuma
and Grace, 1967).

Restriction analysis of the HR-1 virus

revealed submolar restriction fragments in addition to the
standard fragments, suggesting the presence of at least two
different classes of molecules in these cells (Delius and
Bornkamm, 1978, Bornkamm et al., 1980).

The EBV sequences

contained within the submolar restriction fragments have .
been designted 'het', for heterogeneous DNA (Heston et al.,
1982) .
Miller and colleagues subcloned the HR-1 cell line and
4
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recovered two types of clones.

The majority of clones

contained only the standard EBV genome.

However, one

subclone, HR-1 clone 5, contained hypermolar levels of 'het'
DNA (Rabson et al., 1983).

Jenson et al. (1986, 1987)

demonstrated that het DNA comprises an extensively
rearranged and deleted HR-1 genome (Fig. 1).

The defective

genome is maintained by cell-to-cell spread and can be lost
from cell culture (Miller et al., 1985, Kolman, J.L.
personal communication).

HR-1 clone 5 cells spontaneously

enter viral replication and release a mixture of standard
and het viruses (Rabson et al., 1983).

Additionally, only

clones harboring het DNA maintain the ability to induce
early antigen expression in latent EBV (Miller et al.,
1984).
Countryman and Miller (1985) then showed that the
capacity to activate replication can be mapped to one het
DNA fragment.

The het fragment responsible for disrupting

latency is a 2700 bp fragment termed WZhet.

It represents a

recombination and inversion of two regions of EBV DNA (BamHI
W and BamHI Z) which are usually more than 50 Kb apart on
the standard EBV genome (Fig. 2) (Countryman et al., 1985,
Jenson and Miller, 1988) .

WZhet contains only one complete

open reading frame, BamHI Z leftward reading frame 1
(BZLFl), which is inverted relative to its position in the
standard genome (Fig. 2) (Jenson et al., 1986, Jenson et
al., 1987).

It was not immediately clear whether het DNA
5
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disrupted latency by encoding a novel protein or
alternatively, that rearrangements in het DNA activated
expression of a wild type EB viral protein.

It has since

been determined that both the standard and het BZLFl open
reading frames maintain the ability to disrupt the EBV
latent cycle (Chevallier-Greco et al., 1986, Countryman et
al., 1987, Takada et al., 1986).

We have termed the protein

encoded by BZLFl, ZEBRA (Z EB Replication Activator).
Expression and regulation of the ZEBRA protein in the
standard and HR-1 het EB viruses was analyzed.

ZEBRA is

differentially synthesized in these viruses suggesting that
the lytic nature of HR-1 is due to an abnormal regulation of
ZEBRA expression.
ZEBRA was studied.

Additionally, the DNA binding activity of
ZEBRA has a broad DNA binding

specificity which is inhibited by casein kinase II
phosphorylation.

The potential importance of these

properties in regulating the EBV lytic cycle will be
discussed.

6
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Figure 1. Physical map of Epstein-Barr viral DNA in one
cellular subclone of the HR-1

cell line.

represent defective (or het) DNA.

The boxes

Boxes with similar

shading symbolize het DNA sequences which are adjacent to
each other (from Miller et al., 1984).
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Figure 2. Map of WZhet (BamHI het 2.7). The 2.7 Kb WZhet
fragment is capable of disrupting latency.

The fragment

represents intramolecular recombination and inversion of two
regions of EBV DNA (BamHI W and BamHI Z) which are more than
55 Kb apart on the standard EBV genome.

All open reading

frames (horizontal arrows) except BZLFl are truncated (from
Jenson and Miller, 1988).

9
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CHAPTER II
EXPRESSION OF THE BZLFl LATENCY-DISRUPTING
GENE DIFFERS IN STANDARD AND DEFECTIVE
EPSTEIN-BARR VIRUS

INTRODUCTION
Epstein-Barr virus is maintained in immortal B
lymphocytes predominantly in the latent state.

Expression

of lytic cycle products occurs spontaneously in a small
proportion of EBV-infected lymphocytes; however viral
replication can be induced in many more cells by such agents
as phorbol esters, butyrate and serum factors (Bauer et al.,
1985, Luka et al., 1979, zur Hausen et al., 1979).

Virus

from the P3HR-1 subline of the Jijoye Burkitt's lymphoma
also has the capacity to induce EB viral replication (Henle
et al., 1970, Miller et al., 1984).
The P3HR-1 cell line contains two forms of EBV DNA, a
standard genome and a defective (heterogeneous or het)
genome which is extensively deleted and rearranged (Cho et
al., 1984, Heston et al., 1982).

Experiments with cellular

subclones of the P3HR-1 cell line implicated the het DNA in
activating replication of the standard EBV genome (Heston et
al., 1982).

HR-1 clone 16 (HH514-16), which is

representative of the majority of HR-1 subclones, contains
the standard genome but has lost het DNA and with it the
capacity to synthesize viral replicative products
11
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spontaneously.

HR-1 clone 5 (HH543-5), a rare clone which

contains hypermolar levels of het DNA as well as standard
EBV DNA, spontaneously enters viral
al., 1983).

replication (Rabson et

Clone 5 cells release a mixture of standard and

het viruses, the latter of which activate viral replication
when added to cells bearing a latent genome.
The capacity to activate replication has been mapped to
the BZLFl open reading frame, which encodes a protein termed
ZEBRA (Z

EB Replication Activator) or EB1 (Chevallier-Greco

et al., 1986, Countryman and Miller, 1985).

ZEBRA is

responsible for activation of early gene expression
(Countryman et al., 1987).

Whereas the BZLFl open reading

frame is present in both standard and het genomes, in the
latter the reading frame is inverted relative to its
position in the standard genome.

In the het genome, BZLFl

has new upstream and downstream regions as the result of
intramolecular recombinations (refer to chapter I, Fig. I11) (Jenson et al., 1986, Jenson et al., 1987).

This

altered genome configuration suggests that the BZLFl gene
might be aberrantly regulated in het DNA.
Previous experiments which characteerized the ability
of the BZLFl gene product to disrupt viral latency relied
exclusively on gene transfers of plasmids in which
expression of the BZLFl gene was driven by strong
heterologous promoters (Chevallier-Greco et al., 1986,
Countryman et al., 1987, Hardwick et al., 1988, Takada et
12
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al.f 1986).

The purpose of the present experiments was to

study the pattern of ZEBRA expression during the life cycle
of standard and defective EB viruses in Burkitt lymphoma
cells, a natural target.

13
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RESULTS
Properties of the ZEBRA Fusion Protein. A ZEBRA fusion
protein was obtained by cloning the 679 bp Nael-PvuII
subfragment of WZhet in frame with the trpE coding sequences
contained in the pATH 11 vector (Dieckmann and Tzagaloff,
1985).

Since a genoomic fragment was used in the expression

construct, the ZEBRA fusion protein made in bacteria would
not be identical to that made in eukaryotic cells if
eukaryotic ZEBRA is expressed exclusively from spliced mRNAs
(Biggin et al., 1987).

The EBV BZLF1 open reading frame

(ORF) should encode 218 amino acids: 9 amino acids upstream
of the two methionines at the 5' end of the ORF; 167 amino
acids from exon 1 of BZLF1 and 42 amino acids downstream
from the first intron.

If the BZLF1 gene is not spliced in

eukaryotic cells, the 218 amino acid insert included in the
bacterial fusion protein would encompass the entire 209
amino acid BZLF1 ORF.
The calculated molecular weight of the protein encoded
by the EBV insert is 23.3 KDa (Jenson et al., 1988).

The

pATH 11 vector contains sequences coding for a 36 KDa trpE
polypeptide.

The observed electrophoretic mobility of the

trpE-BZLFl fusion protein, 72 KDa, was about 13 KDa larger
than calculated.

The ZEBRA polypeptide from eukaryotic

cells also migrates about 13 KDa slower than expected
(Jenson et al., 1988).

The synthesis of fusion protein was

highly inducible by addition of indoleacrylic acid to HB101
14
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cells transformed with the pATH 11/BZLF1 construct.

After

treatment of the bacterial cell lysate with DNAse I, the
fusion protein accounted for about 50% of the total protein
in the insoluble pellet (Fig. 1).
Detection of Polymorphic ZEBRA Polypeptides by Rabbit
Antisera Raised to the TrpE-BZLFl Fusion Protein.

Initial

experiments evaluated the specificity of the antisera
obtained from rabbits immunized with the trpE-BZLFl fusion
protein.

Post-immune rabbit sera recognized a nuclear

antigen in COS-1 cells transfected with pSV2neo-WZhet and in
HR-1 clone 16 cells treated with TPA (Fig.

2).

Preimmune

rabbit sera did not react with COS-1 cells or HR-1

cells by

immunofluorescence or by immunoblotting (not shown). The
post-immunization rabbit sera did not detect antigens in
untransfected COS-1 cells nor in uninduced clone 16 cells in
an immunofluorescence assay (not shown).
It was known from immunoblot analysis using polyvalent
human sera, as well as a weakly reactive rabbit antiserum
raised to a lac Z-BZLF1 fusion protein, that ZEBRA
polypeptides from various EBV strains have different
electrophoretic mobilities (Countryman et al., 1987).

By

means of chimeric mutants and DNA sequence analysis it was
previously determined that 3 point mutations at amino acid
positions 25, 51 and 73 in BZLF1 account for the 3 KDa
difference in electrophoretic mobility of HR-1 het ZEBRA
(39KDa) and standard HR-1 ZEBRA (36KDa) (Countryman et al.,
15
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1987, Jenson et al., 1988).

There is also a reproducible

difference in electrophoretic mobility of about 1-2 KDa
between ZEBRA from standard HR-1 and EBV strain FF41.

This

mobility difference disappeared when the proteins were
further denatured in 8 M urea; however, even after
denaturation in urea, HR-1 het ZEBRA migrated about 3 KDa
slower than standard HR-1 ZEBRA (D. A. Katz, unpublished
data).
The rabbit antiserum to TrpE-BZLFl recognized the
polymorphic ZEBRA proteins made after transfection of COS-1
cells with the BZLF1 gene from various EBV strains (Fig. 3).
Furthermore, using this serum we showed that the ZEBRA
polypeptide made in lymphoid cells from intact virus
comigrated with the polypeptide made when the encoding
region from that virus was transfected into COS-1 cells.
For example, the ZEBRA polypeptide made in butyrate induced
clone 16 cells co-migrated with ZEBRA expressed in COS-1
cells transfected with pSV2neo- BamHI Z (HR-1) (Fig. 3).
Three higher molecular weight bands of 70-90 KDa were also
detected with antibody to BZLF1 on immunoblots of extracts
prepared from induced clone 16 cells.

These products may

represent ZEBRA oligomers which were not completely
denatured prior to electrophoresis.
Kinetics of ZEBRA expression in cells containing only a
standard EBV genome.

The antiserum was used in a time

course study to determine whether ZEBRA was an early or late
16
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viral protein.

ZEBRA could be detected within 6 hrs after

addition of butyrate to clone 16 cells.

Expression reached

near maximal levels within 2-3 days after addition of
butyrate and remained elevated throughout a two week period.
However, cells cultured for 2 weeks in the absence of
inducing agent failed to express detectable levels of ZEBRA.
The higher molecular weight immunoreactive proteins were
first detected about 3 days after butyrate treatment (Fig.
4) .
Additional kinetic experiments were performed in which
clone 16 cells were induced with butyrate in the presence or
absence of inhibitors of EBV viral DNA synthesis,
phosphonoacetic acid (PAA) or acyclovir (ACV).

Treatment

with these inhibitors did not alter ZEBRA expression.

The

higher molecular weight proteins reactive with the antibody
to BZLF1 were also made in the presence of inhibitors of
viral DNA synthesis (Fig. 5 and data not shown).

The

efficacy of the inhibitors was monitored by assessing the
synthesis of a late viral protein, p21.

This protein, which

was induced in clone 16 cells and recognized by the RM
antiserum 3 and 5 days after induction, was blocked by PAA
(Fig. 5).

When ACV was used, it was found that the drug had

blocked viral DNA replication.

Linear EBV, representing

replicated genomes, was present following butyrate induction
only when ACV was absent (Katz et al., 1989).

As expected,

neither ACV nor PAA affected expression of latent products,
17
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EBNAs, recognized by the RM antiserum (Fig. 5).

These

experiments demonstrated that in clone 16 cells ZEBRA was
not expressed during latency and behaved as an early
replicative protein following chemical induction.
Constitutive Expression of ZEBRA in Cells Bearing Both
Standard and Defective EBV Genomes.

It was of interest to

compare ZEBRA expression in clone 16 cells with its
expression in spontaneously replicating clone 5 cells.

The

polymorphisms of ZEBRA encoded by WZhet and standard BamHI Z
(Fig. 3) were used to monitor expression of the two ZEBRA
variants in clone 5 cells which harbor both standard and
defective genomes.

Clone 5 cells expressed ZEBRA

spontaneously, without addition of inducing agents (Fig. 6).
There was generally a lag in ZEBRA expression after
subculture into fresh medium, but by 2-4 days after
subculture ZEBRA was detected and persisted thereafter.

The

het variant was predominant and was detected before standard
ZEBRA.
The effects of two inducing agents, TPA and butyrate,
were tested in clone 5 cells (Fig. 7).

At 3 and 4 days

after subculture het ZEBRA was made spontaneously, in the
absence of inducer.

In the presence of butyrate, standard

ZEBRA as well as het ZEBRA, were activated.
experiments (not shown), butyrate
expression of standard ZEBRA.

In many

preferentially activated

TPA seemed to induce het

ZEBRA to a greater extent than standard ZEBRA.

These

18
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experiments suggested that there are separate controls on
expression of ZEBRA from the two genomes.
Since ZEBRA persisted in viral cultures at maximal
levels for two weeks after induction (Fig. 4), it was of
interest to determine the stability of the ZEBRA protein.
Following induction with butyrate, clone 5 cells were
treated with either cycloheximide or actinomycin D to
abolish translation or transcription, respectively.

As

expected, the level of ZEBRA protein increased in butyrate
treated cells during the next 48 hours (Fig. 8).

However,

no decrease in ZEBRA protein was observed in cycloheximide
or actinomycin D treated cells during the same time period
(Fig. 8).

These results suggest that ZEBRA is a stable

protein whose half life is greater than 48 hours.
Exogenous Infection with Virus Stocks Containing Both
Standard and Defective Genomes.

Virus stocks prepared from

clone 5 cells, containing a mixture of standard and
defective EBV genomes, were inoculated into EBV genome
negative Burkitt Lymphoma (BL) cells which had been stably
converted by HR-l (CL16) and B95-8 virus strains (Calender
et al., 1987, Seibl et al., 1986).

The converted lines were

used as targets in order to compare expression of the
endogenous standard virus with the superinfecting het and
standard virus mixture.
All 4 EBV converted BL cell lines maintained the virus
in a tightly latent state. In these lines, neither TPA nor
19
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butyrate stimulated expression of the ZEBRA from endogenous
EBV genome (Fig. 9 and data not shown).
(HR-1 clone 16 and

The same viruses

B95-8), however, could be induced in

other cell backgrounds.

When the EBV converted cells were

superinfected by clone 5 virus stocks, het ZEBRA was
markedly induced by TPA treatment (Fig. 9).

Het ZEBRA

expression in these 4 Burkitt Lymphoma lines was not
accompanied by synthesis of standard ZEBRA, as it was in
clone 5 cells.

Nonetheless, expression of the het ZEBRA

protein was associated with the production of a large number
of early antigens (data not shown).
Transcription of BZLF1 in HR-1 Cells Bearing Standard and
Defective EBV Genomes.

Northern blot analysis was performed

to determine whether the observed differences in standard
and het ZEBRA expression were due to regulation at the
transcriptional level. RNA from clone 16 and clone 5 cells
was probed with a 523 bp fragment representing 264 bp
upstream of BZLF and 259 bp of the first coding exon.
prominent mRNAs of 3.5 Kb and 0.9 Kb

Two

were detected one and

two days after butyrate treatment (Fig. 10).

In clone 5

cells the same two mRNAs were expressed spontaneously
without addition of an inducing agent.

In uninduced clone

16 cells there were no transcripts identified with this
probe.

The experiments indicated that differences in ZEBRA

expression by clone 16 and clone 5 cells were likely to be
the result of differences in transcriptional control.
20
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Northern blots were then probed with fragments specific
for the BZLF1 and BRLF1 open reading frames in an attempt to
distinguish between the 3.5 Kb and 0.9 Kb mRNAs.

In induced

clone 16 cells, both mRNAs were recognized by the BZLF1
specific probe while only the 3.5 Kb mRNA was recognized by
the BRLF1 specific probe (Fig. 11).

These results

corroborate the finding that the BRLF1 specific mRNA is
colinear with BZLF1 at the 3' end (Biggin et al., 1987,
Seibl et al., 1987).

B95-8 cells, a marmosset EBV line,

expressed a 15 Kb BZLF1 specific transcript in addition to
the 3.5 Kb and 0.9 Kb transcripts (Fig. 12).
The synthesis of both BZLF1 mRNAs was sensitive to
treatment with cycloheximide, a protein synthesis inhibitor
(Fig. 13).

Additionally, neither mRNA was detected if

cycloheximide was added 8 hours following induction of clone
16 cells with butyrate (Fig. 13).
Kinetics and Stability of BZLF1 specific mRNAs.

RNA was

isolated at various time points following TPA induction of
B95-8 cells in an attempt to determine the kinetics of
transcription of the BZLF1 specific 3.5 Kb and 0.9 Kb mRNAs.
Both mRNAs were detected 2 hours after induction and both
reached maximal levels at 13 hours post induction (Fig. 14).
The half life of these mRNAs was determined by treating
butyrate induced clone 5 cells with actinomycin D and
assessing RNA levels by Northern blot analysis.

Again, both

the 3.5 Kb and 0.9 Kb mRNAs had approximately the same
21
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I

kinetics of expression with a half life of 3.5 hours (Fig.
15).

The half life of these mRNAs is also 3.5 hours in

clone 16 cells and B95-8 cells (data not shown).

22
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DISCUSSION
Since the BZLF1 gene product can activate the
expression of many EBV genes in transfection experiments, it
has been assumed that this gene plays a pivotal role in the
switch between latency and replication in the context of the
intact virus (Chevallier-Greco et al., 1986, Countryman and
Miller, 1985, Hardwick et al., 1988,

Seibl et al., 1986).

However, little is known about the regulation of this gene
in natural infection.

There have been no reports describing

the effects of different variables on expression of ZEBRA
protein in lymphoid cells.

Regulation of expression of the

BZLF1 gene differs in cells with or without het DNA and
these results are summarized in Figure 15.

These

experiments define at least three sets of variables which
affect ZEBRA expression: presence of defective virus, cell
background, and addition of chemical inducers such as sodium
butyrate and TPA.
Defective Virus.

The presence of defective virus was

associated with constitutive ZEBRA expression.

The

defective genomes are easily lost from clone 5 cells (Miller
et al., 1985).

Those clone 5 cells which contain the

defective virus expressed ZEBRA, while those which have lost
het DNA no longer synthesize the ZEBRA polypeptide (Kolman,
J.L., unpublished data).

Parental HR-1 cells, which contain

several different families of defective EBV DNA molecules,
23
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express distinct polypeptides which are reactive with the
anti-BZLFl serum.

Many defective populations activate ZEBRA

synthesis while the loss of defective virus is usually
associated with an absence of spontaneous ZEBRA expression
(J. Kolman, unpublished

data).

Seibl et. al. observed a 40 KDa BZLF1 specific protein
in hybrid-selected translations with RNAs from induced HR-1
cells.
from

They also immunoprecipitated a 35 KDa BZLF1 protein
metabolically labelled cells.

Although they concluded

that the 35 KDa protein was processed from a 40 KDa
precursor, their studies could not distinguish beween
expression of products from the standard and defective HR-1
EBV genomes (Seibl et al., 1986).

However, this system

enabled me to distinguish between the role of standard and
defective viruses in ZEBRA expression.
The polymorphisms of the ZEBRA polypeptide provided a
powerful tool with which to assess ZEBRA expression from the
defective and standard genomes.
most

In the absence of inducers,

of the ZEBRA in clone 5 cells was derived from the

defective genome (Fig. 6,7).

When virus stocks containing

both types of genomes were used to infect EBV converted BL
cells, het ZEBRA was exclusively expressed (Fig.9).

These

results suggest that aberrant controls on ZEBRA expression
in the defective genome are responsible for its high level
of expression.

In related experiments using gene transfer

into BL cells ZEBRA was expressed at high levels from
24
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plasmids containing the rearranged EcoRI het 16 palindromic
fragment; ZEBRA was not made when it was introduced on a
standard BamHI Z fragment (Rooney et al., 1988).

Thus, the

acquisition of new positive regulatory signals as the result
of the genome rearrangements are likely to explain the high
level of spontaneous het ZEBRA expression in clone 5 cells.
A fraction of the ZEBRA protein expressed in clone 5
cells bearing het DNA is derived from the BZLF1 open reading
frame in the standard genome.

This finding suggests that an

autoregulatory loop may exist; het ZEBRA may activate the
expression of standard ZEBRA, either directly or by the
action of other EBV products whose expression is stimulated
by ZEBRA.

The long half life of the ZEBRA may be important

in its role in regulating the EBV lytic cycle and its
possible function during the late phase of viral replication
(Fig. 8).
Cell Background.

Cell background provides an important

influence on ZEBRA expression.

Upon de novo infection of

primary B cells with virus stocks, with or without
defectives, ZEBRA synthesis is not detected (Rooney et al.,
1989).

In EBV converted Burkitt's lymphoma lines there is

"tight" regulation of ZEBRA expression; inducing agents such
as TPA or butyrate, are incapable of activating standard
ZEBRA expression.

This may be explained by the recent

finding that EBV infection of Burkitt's lymphoma lines
results in the integration of the virus rather than its
25
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maintenance as an extrachromosomal plasmid (Hurley et al.,
1991).

Expression may be differentially regulated in

integrated EBV as compared with an EBV episome.
Preferential expression of het ZEBRA in these cells may
be due to a gene dosage effect or may be the result of the
juxtaposition of a TPA responsive element in the het virus.
Nonetheless, high levels of het ZEBRA expression in a BL
cell background does not activate expression of standard
ZEBRA as it does in other cells (Figs. 6 ,7, and 9).
In cell lines in which EBV is less tightly latent, such
as clone 16 (Fig. 3),

Raji, or in vitro EBV immortalized

cord blood B lymphocytes such as

X50-7, ZEBRA is not

synthesized spontaneously but can be activated with chemical
inducers and het DNA.

The B95-8 and FF41 marmoset cell

lines, which spontaneously replicate EBV without requirement
for defective DNA or an inducing chemical, spontaneously
synthesize ZEBRA.

Thus, the tendency of an EBV containing

cell line to exhibit a tightly latent or a productive
phenotype correlates with stringent versus loose control on
ZEBRA expression.

This correlation has been strengthened by

the observation that transfection of a ZEBRA-VP16 fusion
protein can activate high levels of standard ZEBRA
expression in clone 16 cells but not in an EBV converted BL
cell line, BL30/clone 16.(Baumann, Grogan, Gradoville, and
Miller, manuscript in preparation).
The nature of these host cell-specific controls can
26
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only be conjectured.

They may represent positive or

negative regulatory elements.
Chemical Induction.

It seems likely that the pathways by

which chemicals such as TPA and butyrate activate EBV early
gene expression intersect with those which control ZEBRA
gene expression.

This hypothesis can be tested since

inducing agents vary in their effects on cell lines carrying
different EBV genomes.

For example, TPA is a much more

potent inducing stimulus of early antigen synthesis in Raji
cells than butyrate and it was found that ZEBRA expression
is activated to a greater extent in Raji cells by TPA than
by butyrate (data not shown).

However, these experiments

cannot distinguish which replicative genes are TPA
inducible.
The inducing drugs differentially affect standard and
defective EBV.

The standard EBV genome in clone 16, is more

efficiently induced to express ZEBRA by butyrate than by TPA
(Fig. 7, and data not shown).

The defective genome in clone

5, however, is more strongly affected by TPA.

Additionally,

Rooney et. al. have shown through gene transfers that in the
genetic environment of het DNA, het ZEBRA expression is
markedly induced by TPA (Rooney et al., 1988).

A probable

site for the TPA responsive element in the defective DNA is
the promoter element for the MS-EA gene which is positioned
downstream of BZLF1 in het DNA.

This promoter contains a

binding site for the AP-1 transcription factor which is TPA
27
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inducible (Angel et al., 1987, Lee et al., 1987).

Butyrate

may activate expression of ZEBRA by altering the nucleosome
configuration in the cell.

Butyrate has been shown to

inhibit histone deacetylation resulting in histone
hyperacetylation (Candido et al., 1978, Sealy and Chalkley,
1978).
However, the differential effects of chemical inducers
on het versus standard ZEBRA are transient (Fig. 7).

A

likely explanation is that both het and standard ZEBRA
proteins are each capable of stimulating the other.

This

hypothesis is supported by the finding that spontaneous
expression of het ZEBRA protein is eventually accompanied by
expression of the standard ZEBRA protein.
Nature of the control.

These experiments indicate that the

major controls on ZEBRA expression are at the
transcriptional level.

Chemical induction of cells

containing only standard virus such as clone 16, Raji and
B95-8 is invariably associated with marked increases in
BZLF1 mRNA (Figs. 9, 11, 13, and data not shown).

However,

in clone 5 cells which contain a defective virus, BZLF1
specific transcripts are made constitutively and are not
always increased by butyrate treatment.

The level of ZEBRA

mRNAs in these cells varies with culture conditions such as
temperature, cell density, and interval since feeding (not
shown).

These variables probably reflect cellular controls

on the het virus.
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Since this work was completed, Manet et al. reported
the isolation of four BZLF1 specific cDNAs clones: a spliced
BZLF1 with three exons; two bicistronic BRLF1-BZLF1 clones,
encoding an unspliced BRLF1 ORF and the spliced BZLF1 gene;
and a spliced BZLF1 clone with a deleted 5' terminus (Manet
et al. 1989).

In these experiments, only two BZLF1 specific

mRNAs were detected in a number of EBV positive cell lines;
corresponding to the spliced BZLF1 mRNA and one bicistronic
BRLF1-BZLF1 message (Figs. 10, 11, 12).

However, the 0.9 Kb

message is generally of higher abundance than the 3.5 Kb
transcript and may represent more than one BZLF1 transcript.
Additionally, a 15 Kb BZLF1 specific message was detected in
induced B95-8 cells (Fig. 12).

This message may correspond

to the leftward transcript hybridizing to BamHI-W previously
described by Rogers and Speck (1990).

Thus, the message

encoding the entire ZEBRA protein is contained within at
least three transcripts.

However, it has still not been

determined whether ZEBRA is translated from all these mRNAs
in-vivo.
Studies of the kinetics of expression of the 3.5 and
0.9 Kb messages suggest that they may be regulated by
similar cellular controls.

Both messages were detected

within two hours following induction (Fig. 14) and both have
a half life of approximately 3.5 hours (Fig. 15).
These results help clarify previously published results
on BamHI Z transcripts.

Biggin et. al. detected two
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transcripts of 2.8 Kb and 1.0 Kb from BRLF1 and BZLF1,
respectively, in HR-1 superinfected Raji cells treated with
protein synthesis inhibitors and suggested that these
"immediate early" transcripts are derived from the defective
genome (Biggin et al., 1987).

However, under the conditions

of their experiment, they could not ascertain whether the
transcripts were expressed from the Raji genome, the HR-1
standard genome, or the HR-1 defective genome.
Laux et al. showed that these two transcripts could be
detected in the defective Raji cell line after induction
with TPA (Laux et al., 1988).

However, in contrast to

transcripts made after superinfection, those induced by TPA
were not detected in the presence of a protein synthesis
inhibitor, cycloheximide.

They suggested that the mechanism

of activation of replication by superinfection and by TPA
are different (Laux et al., 1988).
These experiments support the findings of Laux et al.
since synthesis of both the 3.5 Kb and 0.9 Kb BZLF1 specific
mRNAs in clone 16 cells were sensitive to inhibition of
protein synthesis with cycloheximide (Fig. 13).

Therefore,

a viral, or possibly cellular protein must be made before
ZEBRA mRNA can be synthesized in cells with a standard
unrearranged genome.

Additionally, de novo protein

synthesis may be continually required for BZLF1
transcription from standard virus since no ZEBRA specific
transcripts were detected in cells which were treated with
30
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cycloheximide 8 hours following addition of butyrate (Fig.
13).

Although BZLF1 transcripts are not detected in any of

the cycloheximide + butyrate treated cells, RNA extracts
from these cells, but not from uninduced cells, consistently
demonstrate a high level of background hybridization with
BZLF1 specific probes.

This suggets that de-novo protein

synthesis may be required for the stabilization of BZLF1
transcripts.

However, in cells containing a defective

virus, transcripts are made constitutively and do not appear
to require new protein synthesis.
Future work will entail a search for differences in the
control mechanisms on BZLF1 in the standard and defective
viruses.

Control may involve repressors encoded by the

virus or the cell as well as transcription factors which are
activated by inducing agents.
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Figure 1.

Appearance of the TrpE BZLF1 fusion protein on a

polyacrylamide gel stained with Coomassie brilliant blue.
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Figure 2.

Reactivity of rabbit antiserum to the TrpE-BZLFl

fusion protein by immunofluorescence.

COS-1 cells were

transfected 3 days previously with pSV2neo/WZhet.
clone 16 cells were treated with TPA for 3 days.

HR-1
The rabbit

antiserum was used at a 1:30 dilution; rhodamine conjugated
anti-rabbit Ig at 1:50.
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ANTISERUM: ANTI BZLFI
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Figure 3.

Reactivity of rabbit antiserum to the TrpE-BZLFl

fusion protein by immunoblottina.

Extracts were prepared

from HR-1 clone 16 cells which were untreated (C16) or
treated with butyrate for 3 days (C16+B).

COS-1 cells were

transfected with pSV2neo plasmids containing WZhet, the
BamHI Z fragment from EBV strains FF41, HR-1, or no insert.
The immunoblot was probed with a 1:100 dilution of rabbit
antiserum to BZLFI.
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Figure 4.

Kinetics of ZEBRA expression after butvrate

induction of HR-1 clone 16 cells.

Each time point

represents an extract of 2 X 106 cells which was
electrophoresed through a 10%

SDS-polyacrylamide gel.

immunoblot was probed with rabbit
TrpE-BZLFl fusion and I

antiserum to the

- protein A.
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Figure 5.

Lack of effect of phosohonoacetic acid fPAAt on

ZEBRA expression in HR-1 clone 16 cells.
uninduced or induced with butyrate.
cells was also treated with PAA.

Cells were

An aliquot of induced

Cell extracts were

analyzed after 3 or 5 days on duplicate immunoblots with
rabbit anti-BZLFl serum or polyvalent human antiserum, RM,
which recognizes a p21 late protein.

ZEBRA expression is

unaffected by PAA but p21 synthesis is inhibited.
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Figure 6.
cells.

Constitutive Expression of ZEBRA, in HR-1 clone 5

Duplicate experiments are illustrated.

Extracts

were prepared at intervals after splitting the cells at a
ratio of 1:4 (left) or 1:5 (right).

There is a delay in

ZEBRA expression after the cells are split.

Beginning at

2-4 days after subculture ZEBRA is expressed spontaneously,
without addition of an inducing agent.

The het variant is

more abundant than standard ZEBRA.
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Figure 7.

Effects of inducing agents on expression of the

two ZEBRA variants in HR-1 clone 5 cells.

Uninduced cells

express mainly the het variant; after addition of TPA or
butyrate both the het and standard ZEBRAs are expressed.
TPA has a greater effect on het ZEBRA whereas butyrate
preferentially stimulates the standard variant.
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Figure 8.

Stability of the ZEBRA protein.

Clone 5 cells

were induced for three days with butyrate at which time
transcription or protein synthesis were inhibited with
actinomycin D or cycloheximide, respectively.

Cells were

then harvested at various time points following inhibition.
Each time point represents an extract of 1 X 106 cells which
were electrophoresed through a 10% SDS-polyacrylamide gel.
The immunoblot was probed with rabbit anti-BZLFl serum.
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Figure 9.

Expression of ZEBRA after infection of Burkitt

lymphoma cell lines BL30 and BL2 stably converted with the
B95-8 and HR-1 clone 16 strains of EBV.

The cells were

treated (+) or untreated (-) with TPA and infected (+) or
uninfected (-) with clone 5 virus stocks.

Western blots

prepared 48 hrs after infection were reacted with anti-BZLFl
serum.

Following infection of converted BL30 or BL2 cells

the het ZEBRA is expressed in the presence of TPA.

However,

in these cells, the standard ZEBRA from clone 16 or B95-8
virus is not expressed after TPA induction or
superinfection with clone 5.
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Figure 10.

Northern blot analysis of BZLF1 transcription in

HR-1 clone 16 and clone 5 cells.

RNA was prepared from

uninduced clone 16 cells 1 day after subculture and from
butyrate treated clone 16 cells at one and two days after
subculture.

RNA was prepared from clone 5 cells two days

after subculture in the absence or presence of butyrate.
Both blots were probed with a 523 bp subfragment of mutant
80 of WZhet (Countryman et al., 1987).

The filter

containing clone 16 RNAs was stained with methylene blue to
demonstrate that the level of ribosomal RNAs from the
uninduced and induced cells was similar.
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Figure 11.

Localization of BZLF1 specific transcripts.

RNA

was prepared from uninduced and butyrate treated clone 16
cells one day after induction.

RNAs were electrophoresed in

duplicate and Northern blots were probed with a 395 bp BZLF1
specific fragment or a 538 bp BRLF1 specific fragment.
the 3.5 Kb and 0.9 Kb mRNAs are detected with the BZLF1
probe whereas only the 3.5 Kb mRNA is detected with the
BRLF1 specific probe.
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Figure 12.

Northern blot analysis of BZLF1 transcription in

B95-8 cells.

RNA was prepared from uninduced and TPA

treated B95-8 cells.
subfragment of BZLF1.

The blot was probed with a 627 bp
A 15 Kb mRNA is detected in addition

to the 3.5 Kb and 0.9 Kb BZLF1 specific mRNAs.
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Figure 13.

Protein synthesis is required for BZLF1

transcription following butvrate induction.

Clone 16 cells,

which contain only standard EBV DNA, were untreated or
induced with butyrate.

A) An aliquot of the butyrate

treated cells was treated with the protein synthesis
inhibitor, cycloheximide.

After 24 hours RNA was harvested

from the three groups of cells and probed on a Northern blot
with a 627 bp subfragment of BZLF1.

The two BZLF1 specific

mRNAs, 3.5 Kb and 0.9 Kb, are detected in butyrate treated
cells but are not expressed in the presence of
cycloheximide.

B) Cycloheximide was also added to different

cell aliquots at 1, 2, 4, and 8 hours following butyrate
induction.

RNA was harvested 48 hours after induction and

similarly probed on a Northern blot with the BZLF1
subfragment.

The BZLF1 specific mRNAs were not detected in

any of the cyloheximide treated cells.
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Figure 14.

Kinetics of BZLF1 transcription in TPA induced

B95-8 cells.
1 X 106 cells.

Each time point represents RNA harvested from
The Northern blot was probed with the 627 bp

BZLF1 subfragment.

The 3.5 Kb and 0.9 Kb BZLF1 specific

mRNAs are detected simultaneously.
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Figure 15.

Stability of BZLF1 specific mRNAs in butyrate

induced clone 5 cells.

Clone 5 cells were induced with

butyrate for 2 days prior to inhibition of transcription
with actinomycin D.
points.

RNA was harvested at various time

Each time point represents RNA from 1 X 106 cells

and the blot was probed with the 627 bp BZLF1 subfragment.
The 3.5 Kb and 0.9 Kb BZLF1 specific mRNAs have similar
stabilities.
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Figure 16.

Differences in regulation of BZLF1 expression in

HR-1 cells with or without het DNA.

Clone 16 cells, which

lack het DNA, express latent products (shaded nuclei) and
spontaneously enter the replicative cycle at a low rate
(0.1% of cells).

Clone 5 cells, which harbor het DNA,

spontaneously produce virus.

BZLF1 expression was studied

in untreated cells or after induction with TPA or butyrate.
BZLF1 specific transcripts were detected by Northern
blotting and ZEBRA protein expression was assayed by Western
blotting with a monospecific antiserum (from Miller, 1990).
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DIFFERENCES IN REGULATION OF BZLF1 IN
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CHAPTER III

DNA BINDING ACTIVITY OP ZEBRA: THE EPSTEIN-BARR
VIRAL REPLICATION ACTIVATOR

INTRODUCTION
Epstein-Barr virus infection of lymhoid cells, either
in-vitro or in-vivo, results in lymphocyte immortalization
and viral latency (reviewed Miller, 1990a).

Several groups

have now shown that expression of the EB viral gene, BZLF1
results in a switch to the lytic viral life cycle
(Countryman and Miller, 1985, Chevallier-Greco et al, 1986,
Takada et al., 1986).

The mechanism by which the BZLF1 gene

product, ZEBRA, activates the replicative cycle has not yet
been determined.
Recently, Farrell and co-workers determined that exon
II of ZEBRA shares homology with the basic domain of the
Fos/Jun oncogene family (Fig. 1) (Farrell et al., 1989).
Fos/Jun related proteins have previously been shown to bind
the canonical AP-1 site (TGAGTCA), and Farrell et al. (1989)
showed that ZEBRA bound an AP-1 consensus sequence located
in the promoter of an EBV early gene, MS-EA (Angel et al.,
1987, Lee et al., 1987, Hope and Struhl, 1987, Farrell et
al., 1989).

All of the Fos/Jun related proteins require

dimerization for DNA binding and have been shown to dimerize
through a leucine zipper motif, a region containing leucines
at heptad intervals (Abel and Maniatis, 1989, Agre et al.,
64
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1989, Gentz et al., 1989, Kouzarides and Ziff, 1988, 1989,
Landschulz et al., 1988, Neuberg et al., 1989a, SassoneCorsi et al., 1988, Schuerman et al., 1989, Sellers and
Struhl, 1989, Vinson et al., 1989). ZEBRA, however, does not
contain a leucine zipper dimerization domain downstream of
its basic domain.

Additionally, ZEBRA has been shown to

bind to sites which deviate from the AP-1 consensus sequence
(Chang et al., 1990, Flemington and Speck, 1990b, Lieberman
and Berk, 1990, Packham et al., 1990, Taylor et al., 1991a,
Urier et al., 1989).

Thus, it was of interest to define the

domains of the ZEBRA protein required for DNA binding and
determine whether ZEBRA binds DNA as a dimer.
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RESULTS
Determination of the ZEBRA DNA Binding Domain by Deletional
Mutagenesis.

A BZLF1 cDNA obtained from Ra j i cells was

cloned in frame with the trpE coding sequences contained in
the pATH 11 expression vector (Fig. 2B).

The 75 kilodalton

(Kd) fusion protein bound a 20 base pair (bp)
oligonucleotide which contains an AP-1 consensus sequence
(MS-AP-1) derived from the promoter of the EBV early gene,
MS-EA (Figs. 2C, 2D, Z1_245) .

Several deletion mutants

defined the domain of the protein which bound the AP-1 site
(Figs. 2C, 2D).

All of the mutants exhibited some

temperature sensitive DNA binding activity.

Mutant ZU1_245

encoded the smallest protein which behaved like the wild
type ZEBRA (Z1_2A5) in binding DNA both at room temperature
and at 4C (Fig. 2A).

However, even this mutant did not bind

DNA as well at 4C as the wild type Z.|_245.

The region of

ZEBRA encoded by exon II, which shares homology with the Fos
basic domain (Farrell et al., 1989), was insufficient to
elicit DNA binding activity (Fig. 2C, 2D, Z16a_202) .

Although

Z 11i_159 bound DNA unstably (see smear, Fig. 2C) at room
temperature (22°C) and Z172_245 did not bind DNA under these
conditions (Fig. 2C), both mutant proteins bound DNA at 4°C
(Fig. 2D).

Deletion of the 18 carboxyl amino acids of ZEBRA

resulted in a mutant (ZV227) which bound the AP-1 site at
room temperature, but not at 4°C (Figs. 2C, 2D) .
Furthermore, all the ZEBRA deletion mutants showed the same
66
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pattern of binding to the divergent AP-1 sites, ZIIIA and
ZIIIB, present in the BZLF1 promoter (data not shown, refer
to chapter IV).

Thus, ZEBRA amino acids 172-227 are

required for DNA binding although neighboring sequences may
influence protein folding or stability under some
temperature conditions.
General DNA Binding Activity of ZEBRA mutants.

DNA binding

of ZEBRA mutants was also analyzed by the ability of ZEBRA
proteins to bind an array of DNA sequences.

Z,.^ as well as

the unspliced ZEBRA protein from rearranged het DNA, WZ.,.
167(+41) (which contains 167 amino acids from the first exon of

Zhet plus 41 amino acids from the first intron), were
electrophoresed in an SDS-polyacrylamide gel, blotted onto
nitrocellulose and incubated with radiolabeled pSV2neoWZhet
DNA.

Suprisingly, both proteins bound DNA, and the

unspliced Zhet protein appeared to have a greater intrinsic
DNA binding potential than the wild type ZEBRA protein,
(Fig. 3A).

Whereas pSV2neoWZhet contains an AP-1 binding

site, identical results were obtained when the proteins were
incubated with radiolabeled pATH vector DNA (data not
shown).

In an attempt to determine whether a bacterial

protein, or TrpE, which is present at the 5' terminus of the
ZEBRA constructs is affecting DNA binding, the DNA binding
of bacterial extracts as well as TrpE was analyzed.
Bacterial extracts, cells transformed with the trpE vector
as well as TrpE- WZ.,_167(+41) were electrophoresed and stained
67

R eproduced w ith perm ission o f the copyright owner. Further reproduction prohibited w itho ut perm ission.

with Coomassie brilliant blue (Fig. 3B).

An identical gel

was transferred to nitrocellulose and probed with pSV2neo
WZhet.

While several low molecular weight bacterial bands

were observed in all lanes, TrpE did not bind DNA and TrpEWzi-167(+41) a<?a;*-n bound DNA strongly (Fig. 3C) .
The location of this general DNA binding domain was
mapped by deletional mutagenesis of TrpEConstruction of the deletions is described in the
Experimental Procedures and the extent of the deletions is
shown in Fig. 4A.

All deletion proteins were stably

expressed as assayed by coomassie blue staining of an SDSpolyacrylamide gel (data not shown).

The results of the

general DNA binding assay indicated that the smallest clone
capable of binding DNA was WZ133_167(+41) (Fig. 4B) .
Interestingly, WZ133_167(+4) did not bind DNA suggesting that
intron sequences from WZhet were important for the general
DNA binding ability of this protein (Fig. 4B).

A clone

containing only the basic domain of the ZEBRA protein
encloded by exon II, Z168_202(+4), was not able to bind DNA in
this assay (data not shown).
Site Directed Mutagenesis of the ZEBRA Basic Domain.

The

region of ZEBRA encoded by the second exon of BZLF1 (aa 168202) is partially homologous to the basic region of Fos
(Fig. 1, 5A).

It has recently been shown that amino acids

144-146 and 154-156 are required for the DNA binding ability
of Fos (Neuberg et al.,1989b).

These basic amino acids are
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conserved at positions 178-180 and 188-190 of ZEBRA exon II.
Whereas ZEBRA exon II sequences were not necessary for the
general DNA binding of the protein, they were necessary for
binding to the AP-1 heptamer (Figs. 2 and 4).

Therefore, we

were interested in determining whether the same basic amino
acids contribute to the specific DNA binding activity of
ZEBRA.

The ZEBRA residues were mutated from lys-arg-tyr to

glu-glu-leu and arg-lys-cys to glu-glu-ser, respectively
(Fig. 5A, courtesy E. Flemington).

These mutations

abrogated DNA binding to the consensus (MS-AP-1) as well as
divergent AP-1 sites (ZIIIA and ZIIIB)
Flemington).

(Fig. 5B, courtesy E.

Equivalent amounts of the in vitro translated

wild type and mutant proteins were used in each reaction
(data not shown).

These results demonstrate that the same

basic residues in ZEBRA and Fos are required for binding to
AP-1 and related sequences.

However, deletional mutagenesis

showed that these basic residues are necessary but not
sufficient for sequence specific DNA binding (Fig. 2).
ZEBRA Binds DNA as a Stable Homodimer. Proteins which bind
palindromic DNA binding sites have generally been shown to
bind DNA as a dimer, where each protein binds the dyad half
site (reviewed in Johnson and McKnight, 1989).

Since ZEBRA

binds a consensus sequence with two dyad half sites
(TGAGTCA) and contains homology to the Fos/Jun dimeric
proteins (Abate et al., 1990, Farrell et al., 1989, Hope and
Struhl, 1987, Kouzardies and Ziff, 1988, Landschulz et al.,
69
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1988, Sassone-Corsi et al., 1988), the hypothesis that ZEBRA
also binds DNA as a homodimer was tested.
The method used by Hope and Struhl (1987) to show that
the GCN4 protein bound DNA as a dimeric protein was
utilized.

When proteins are complexed to DNA on an

acrylamide gel, the mobility of the complex is proportional
to the molecular weight of the protein.

When Z.,_245 was

analyzed by gel retardation analysis its mobility was less
than that of the truncated ZEBRA binding protein, Z141_245
(Figs. 2 and 6).

In order to determine whether ZEBRA bound

DNA as a homodimer, a protein lysate containing Z1.245 and
z141-245 were denatured together in 6M urea and then renatured
prior to analysis by gel mobility.

A shifted complex of

intermediate mobility, in addition to the two complexes
observed when either of these proteins bound DNA separately,
was observed (Fig. 6, lane (Z1_2A5 + Z141_245)u) .

The detection

of an intermediate sized band suggests that this complex is
composed of a heterodimer of the individual proteins.
This method has been successfully used to show that the
bovine papilloma virus E2 protein and yeast transcriptinal
activator bind DNA as a dimer and trimer, respectively
(Dostatni et al., 1988, Giri and Yaniv, 1988, McBride et
al., 1989, Sorger and Nelson, 1989).

Furthermore, no

heterodimer complex was formed if the ZEBRA proteins were
mixed following renaturation; indicating that complex
association occurs immediately after dissociation and is
70
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I

stable in the absence of DNA (Fig. 6, lane
245)u) •
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+ (Z141_

DISCUSSION
A Comparison of ZEBRA and Fos DNA Binding Domains.

The

construction and expresssion of ZEBRA deletion mutants in E.
coli enabled a determination of the domains within the ZEBRA
protein which are required for DNA binding.

These studies

indicate that the region 3' to the ZEBRA basic domain (aa
199-227) is required for DNA binding.

The carboxy-terminal

18 amino acids (228-245), while not strictly required for
DNA binding, may also contribute to dimer formation and/or
protein stability since mutants lacking this region bind DNA
in a temperature sensitive fashion (Figs. 2C and 2D).

These

results are consistent with those of Packham et al. who
found that mutants which deleted the same regions of exon 1
or 3 bound DNA in a salt dependent manner, whereas the wild
type protein bound DNA under all conditions (Packham et al.,
1990).
Site directed mutagenesis of c-fos previously
identified the amino acids necessary for DNA recognition of
the Fos/Jun complex (Neuberg et al., 1989b).

Mutagenesis of

Fos amino acids 144-146 or 154-156 completely abrogated DNA
binding (Neuberg et al., 1989b).

The corresponding amino

acids are conserved in the basic domain of ZEBRA exon II and
proteins mutated in these positions were unable to bind any
of the DNA binding sites (MA-AP-1, ZIIIA, or ZIIIB) (Fig.
5).

These results suggest that while the DNA binding

specificities of Fos and ZEBRA differ, the same two clusters
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of basic amino acids are necessary for the specific DNA
binding ability of both proteins.

Further work is needed to

define the amino acids in the basic region which confer the
unique binding specificities of Fos and ZEBRA (refer to
chapter IV).
General DNA Binding of the ZEBRA Protein.

The region

responsible for the ability of the unspliced het ZEBRA
protein to bind DNA in a nitrocellulose filter binding assay
has been localized to the 35 carboxy-terminus amino acids in
exon I (aa 133-167) and the 41 amino acids present in the
first intron (Fig 4).

The residues within the carboxy

terminus as well as the intron are highly basic, a
characteristic of many DNA binding domains.

It is not clear

whether het ZEBRA is ever expressed in-vivo in this
unspliced form, but a cDNA corresponding to the unspliced
standard ZEBRA has never been detected (Biggin et al., 1987,
Manet et al., 1989).
This filter binding method has previously been used to
map the intrinsic DNA binding domains of the v-myb and c-myc
proteins (Klempnauer and Sippel, 1987, Dang et al., 1989).
The intrinsic DNA binding domain of v-myb has also been
shown to confer sequence specific DNA binding potential
(Klempnauer and Sipper, 1987, Biedenkapp et al., 1988,
reviewed in Luscher and Eisenman, 1990b).

However, the

region of c-myc necessary for its nonspecific DNA binding
does not include the basic, helix-loop-helix and leucine
73
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zipper domains of the protein which were required for its
sequence-specific DNA binding potential (Blackwood and
Eisenman, 1991, Blackwell et al., 1990, Dang et al., 1989,
Prendergast and Ziff, 1989, reviewed in Luscher et al.,
1990a).

Thus, the importance of nonspecific DNA binding

domains in both c-myc and ZEBRA has yet to be determined.
Function of ZEBRA Exon III.

Unlike all other identified

transcription factors which bind the AP-1 consensus
sequence, ZEBRA does not contain a leucine zipper directly
adjacent to the basic region (Landschulz et al., 1988,
Vinson et al., 1989).

While ZEBRA exon III (aa 199-245) is

not homologous to any known dimerization domain (Vinson et
al., 1989), ZEBRA binds DNA as a homodimer (Fig. 6) and this
region is required for specific binding

(Figs. 2C and D).

It has been hypothesized that this domain forms an alpha
helix and that dimerization involves a coiled coil
interaction (Flemington and Speck, 1990c, Kolman et al.,
1991, Lieberman and Berk, 1990, Packham et al., 1990, Taylor
et al., 1991a).

Moreover, O'Shea and colleagues (1989) have

hypothesized that the leucine zipper motif forms a coiled
coil structure and have recently shown that the x-ray
structure of the leucine zipper is a coiled coil (Rasmussen
et al., 1991).

Both ZEBRA exon III and the leucine zipper

domain contain the 4-3 hydrophobic repeat necessary for
generation of a coiled coil structure (O'Shea et al., 1989,
Flemington and Speck, 1990c).
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The existence of different leucine zipper and coiled
coil motifs is important in regulating DNA binding of
various proteins.

ZEBRA, as well as the Fos and Jun

protooncogenes and the yeast regulatory protein, GCN4 all
bind the TPA response element (AP-1, TGAGTCA).

However, the

dimerization potentials of these proteins are very specific.
A GCN4 leucine zipper homodimerizes whereas a Fos zipper
dimerizes specifically with Jun and Jun dimerizes with
itself and Fos (Kouzarides and Ziff, 1989, Neuberg et al.,
1989a, Sellers and Struhl, 1989, Nakabeppu and Nathans,
1989) .

While ZEBRA has the potential to bind DNA as a

homodimer, heterodimerization with a leucine zipper protein
or a yet unidentified protein may be important for the
induction of cellular genes and/or the negative regulation
of ZEBRA responsive genes.
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Figure 1. Homology among basic DNA binding domains of BZLF1

and the AP-1 family of proteins.
Farrell et al. (1989).

Data are derived from

Positions of the various amino acids

are as follows: BZLF1, amino acids 175-196; cFos,140-161;
cJun, 264-285; and GCN4, 228-249.

Most of the homology

consists of positively charged residues (arginines, R and
lysines, K) (from Miller, 1990b).
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Figure 2.

DNA binding activity of ZEBRA mutants.

Structure of ZEBRA deletion mutants.

(A)

The ZEBRA cDNA is

shown at the top (Manet et al., 1989) and clones are
designated according to the ZEBRA amino acids present in the
construct.

ZA111_159 is named according to the amino acids

which have been deleted.

Z,.167 was derived from genomic

WZhet DNA (Taylor et al., 1989).

Translated sequences which

are derived from ZEBRA intron sequences are indicated by a
hatched bar and sequences from the expression plasmid
polylinker are indicated by a stippled bar.
of TrpE-ZEBRA fusion proteins in bacteria.

(B) Expression
Total protein

from bacteria which carried various TrpE-ZEBRA deletion
proteins was resolved by SDS-polyacrylamide gel
electrophoresis and stained with Coomassie brilliant blue.
The fusion protein is indicated with dots in each lane. (C)
Gel retardation assay showing binding of TrpE-ZEBRA deletion
mutants to a 20 bp 32P-labeled oligonucleotide containing
the AP-1 consensus sequence (Farrell et al., 1989).

Extract

from bacteria transformed with the trpE plasmid, pATH 11,
was used as a negative control (vector lane). Binding
reactions and electrophoresis were performed at room
temperature (RT,22C).

Complexes were electrophoresed on a

4% acrylamide gel in 0.5X TBE.

(D) Gel retardation assay of

the same TrpE-ZEBRA deletion mutants performed as in (C)
except that binding reactions and electrophoresis were
carried out at 4C.
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Figure 3. Non-specific DNA binding of ZEBRA proteins.

(A)

Z.|_245 and WZ.|_167(+41) were electrophoresed on a 10% SDSpolyacrylamide gel and blotted onto nitrocellulose.

The

blot was then incubated with 32P-labeled PSV2neoWZhet and
analyzed by autoradiography.

(B) Protein extracts from E.

coli AG1 cells, AG1 cells transformed with the trpE pATH
expression vector, and cells transformed with trpE-WZ1
were analyzed by Coomassie brilliant blue staining of an
SDS-polyacrylamide gel. (C) An identical gel was
transferrred to nitrocellulose and analyzed by
autoradiography following incubation with 32P-labeled
PSV2neoWZhet.

Identical results were obtained following

incubation with 32P-labeled pATH vector DNA (data not
shown).

81

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

Probe: pSV2neo WZhet

Coomassie blue
stain

pSV2neo WZhet

R eproduced w ith perm ission o f the copyright owner. Further reproduction prohibited w ith o u t perm ission.

Figure 4• Mapping the non-specific DNA binding domain of
^ 1-167(+4D*

Structure of WZ deletion mutants.

The

structure of WZhet is shown at the top; a bar indicates an
exon and a line denotes an intron (Jenson et al., 1988).
Clones are designated according to the WZhet amino acids
present in the construct. Amino acids denoted in parentheses
refer to those amino acids which are translated from intron
sequences.

(B) Proteins extracts were prepared from induced

AG-1 cells harboring trpE expression plasmids containing
^ 1-167(+41)' ^ 1-88' ^ 133-167(+41)' an<^ ^ 133-167(+4)*

Extracts Were

electrophoresed on an SDS-polyacrylamide gel and then
transferred to nitrocellulose.

The blot was probed with

32P-nick translated PSV2neoWZhet and analyzed by
autorad iography.

83

R eproduced w ith perm ission o f the copyright owner. Further reproduction prohibited w itho ut perm ission.

BZLF 1 - W Zhet Clones
EXON

I
I SI

WZhet

lf.7

EXON J
III
J

EXON II

44

n

7 .3n
■«

ii •

4 jjj

p A T H Derivatives

W Z I-lh7(+ 41)

W Z i-xx

WZi33.|ft7(+4i)
w z !33-167(+4)

B Z L F 1-W Zhet Clones

=

? I

£
kD
MO84-

47-

P rn lv . P S V 2 ik ' o W Z h el

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 5. Effect of point mutations in the basic domain of
ZEBRA.

(A) Amino acid sequences of human c-fos exon III (aa

132-167)

(van Straaten et al., 1983) and BZLF1 exon II (aa

168-202)

(Biggin et al., 1987).

The conserved residues in

this highly basic domain are indicated by lines (Farrell et
al., 1989).

ZEBRA mutants were obtained by site directed

mutagenesis of the BZLF1 cDNA cloned in SP64.

Amino acids

178-180 and 187-189 were changed as shown for Z-M178-80 and
Z-M187-89, respectively.

(B) Gel retardation assay

demonstrating the inability of ZEBRA constructs mutated at
aa 178-180 (Z-M178-80) or 187-189 (Z-M187-89) to bind MS-AP1, ZIIIA, or ZIIIB.

The wild type (Z-WT) and mutated ZEBRA

constructs (Z-M178-180 and Z-M187-189) were transcribed invitro with SP6 polymerase and translated in a wheat germ
extract.

Equivalent amounts of the resulting translated

proteins were each incubated with the following 32P-labeled
oligonucleotide probes: MS-AP-1, ZIIIA, and ZIIIB (see
Experimental procedures for a listing of these sequences).
These complexes were then resolved by gel electrophoresis on
a 4% acrylamide gel in 0.5X TBE.
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Figure 6 . ZEBRA binds DNA as a stable homodimer.

Z 1-245 anc^

zui-245 were dissociated with urea and then reassociated
either separately (Z^jU + Z141_245u) or together ((Z1_24S + Z14l_
245)u ) prior to gel retardation analysis.

Proteins were used

in a gel binding assay with the 20 bp 32P-labeled
oligonucleotide containing the AP-1 consensus sequence.
The various protein extracts were incubated with the
oligonucleotide probe and 1 ug poly dldC in binding buffer
for thirty minutes prior to electrophoresis.

Binding

reactions and electrophoresis were performed at room
temperature (RT,22C) and complexes were electrophoresed on a
4% acrylamide gel in 0.5X TBE.
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CHAPTER IV

ZEBRA AND FOS DIFFER IN THEIR DNA BINDING
SPECIFICITIES FOR SITES IN THE
EPSTEIN-BARR VIRAL BZLF1 PROMOTER

INTRODUCTION
Epstein Barr Virus (EBV) persists in lymphoid cells in
a latent state but can be activated in vitro by phorbol
esters, butyrate or expression of a virally encoded gene,
ZEBRA (Chevallier-Greco et al., 1986, Countryman et al.,
1985, Gradoville et al., 1990, Luka et al., 1979, Taylor et
al., 1989, van Straaten et al., 1983).

The mechanism by

which ZEBRA initiates the cascade of viral replication has
been the focus of much study.

Numerous groups have found

that ZEBRA directly transactivates several promoters of
lytic cycle genes, including a region integral to the EBV
lytic origin of replication (Chavrier et al., 1989,
Chevallier-Greco et al., 1986, Flemington et al., 1990,
Gradoville et al., 1990, Hammerschmidt et al., 1988,
Hardwick et al., 1988, Kenney et al., 1989, Lieberman et
al., 1990, Urier et al., 1989).
Exon II of ZEBRA is homologous to the basic domain of
the Fos/Jun proto-oncogene family (Farrell et al., 1989).
In Fos/Jun complexes, this domain has been shown to interact
directly with a DNA heptamer known as the TRE or AP-1 site
89
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(TGAGTCA)

(Angel et al., 1987, Lee et al., 1987, Neuberg et

al., 1989b).

It was determined that ZEBRA shares the

ability of the Fos/Jun complex to bind an AP-1 consensus
site (Farrell et al., 1989).

An AP-1 consensus sequence

(MS-AP-1) is located in the promoter of an EB early gene,
BSLF2-BMLF1 (MS-EA) (Farrell et al., 1989).

ZEBRA can

transactivate transcription through this site, although it
is not yet clear whether AP-1 sequences are required for
transactivation of EB viral genes in infected lymphocytes
(Holley-Guthrie et al., 1990, Urier et al., 1989).
ZEBRA also binds sites on the EBV genome which deviate
from the AP-1 consensus sequence (Flemington and Speck,
1990b, Lieberman and Berk, 1990, Lieberman et al., 1990,
Packham et al., 1990, Urier et al., 1989).

The

autoregulated BZLF1 (ZEBRA) promoter contains three
divergent AP-1 elements (Flemington and Speck, 1990b).

Two

sites, TGAGCCA (ZIIIA) and TTAGCAA (ZIIIB), 105-129 bp
upstream of the transcriptional start site are arranged in a
tail to tail fashion and are separated by 6 nucleotides.

An

additional AP-1 sequence, TGACATCA (Z-AP-1 octamer), is
located further downstream at -67.

This sequence, which was

first identified in the iun promoter by Angel et al.,
mediates activation by TPA and Jun/AP-1 (Angel et al.,
1988).

Recent work has shown that although this site is TPA

inducible in the ZEBRA promoter, it does not appear to be
transactivated by ZEBRA (Flemington and Speck, 1990a,
90
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1990b).
Since both ZEBRA and Fos/Jun are involved in
transcriptional regulation of gene expression it was
important to compare the DNA binding activities of these
proteins.

Therefore, we studied the relative DNA binding

affinities of ZEBRA and a Fos-GCN4 chimera for the divergent
AP-1 sites found in the autoregulated BZLF1 promoter.
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RESULTS
Binding of ZEBRA and Fos-GCN4 to Oligonucleotides Bearing
Single AP-1 and "AP-1 Like" Sequences. It was previously
shown that ZEBRA footprinted sites ZIIIA at -129 (TGAGCCA)
and ZIIIB at -116 (TTAGCAA), but not the Z-AP-1 octamer
sequence (TGACATCA) 67 bp upstream of the BZLF1
transcriptional start site (Flemington and Speck, 1990b,
Fig. 1A).

A gel retardation assay was used to compare the

relative affinities of ZEBRA and Fos-GCN4 for these sites in
the BZLF1 promoter.

The Fos basic domain has been shown to

bind the AP-1 consensus site as a homodimer when fused to
the GCN4 leucine zipper (Hope and Struhl, 1987, Kouzarides
and Ziff, 1989, Sellers and Struhl, 1989).

A Fos-GCN4

chimera, expressed as a trpE fusion protein, bound the MSAP-1 consensus site but not ZIIIB or ZIIIA.

ZIIIB differs

from the consensus AP-1 site at 3bp and ZIIIA contains a
single base pair change from the consensus heptanucleotide
AP-1 sequence (Fig. 3B).

Fos-GCN4 bound the Z-AP-1 octamer

with high affinity whereas ZEBRA interacted only weakly with
this sequence.

Thus, Fos-GCN4 binds the AP-1 octamer and

heptanucleotide sequences while ZEBRA binds the MS-AP-1,
ZIIIA and ZIIIB sites with relatively high affinity (Fig.
IB).

The trpE-ZEBRA and trpE-Fos-GCN4 fusion proteins were

derived from the urea solubilized fraction of total E. coli
protein extracts.

ZEBRA and Fos-GCN4, expressed in this

system, bind DNA as homodimers (refer to chapter III, Kolman
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et al., manuscript in preparation, Taylor et al., 1991b).

A

control extract of bacterial protein did not exhibit
specific binding to any of these sites (data not shown).
Binding of ZEBRA and Fos-GCN4 to an Oligonucleotide
Containing Two ZEBRA Response Elements, ZIIIA and ZIIIB.
Since the ZIIIA and ZIIIB sites are only separated by 6
nucleotides in the ZEBRA promoter, we studied the ability of
ZEBRA and Fos-GCN4 to bind both sites simultaneously.

An

oligonucleotide termed "Double" which includes both sites in
the orientation found in the BZLF1 promoter was used in gel
band shift assays.

ZEBRA was able to bind two sites on this

oligonucleotide simultaneously as demonstrated by the
appearance of two band shift products in a mobility shift
assay (Fig. IB).

Suprisingly, the Fos-GCN4 chimera, which

did not bind a single ZIIIA or ZIIIB site, was able to bind
the Double oligonucleotide (ZIIIA + ZIIIB) generating a
slower migrating complex (Fig. IB).
The order of binding to sites on the Double
oligonucleotide was then studied.

Serial dilutions of ZEBRA

and Fos-GCN4 were incubated with 4 X 10'13M of 32P labelled
Double probe.

At low protein concentrations (0.25 ul),

ZEBRA only bound a single site on the oligonucleotide (one
shifted complex) while at high concentrations (5 ul) it
began to interact with both sequences

on a single

oligonucleotide molecule (two shifted complexes)

(Fig. 2A).

However, Fos-GCN4 generated a single complex of slower
93
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mobility with the Double probe, regardless of protein
concentration (Fig. 2B).
Nucleotide Specificity of ZEBRA and Fos-GCN4 Binding Sites.
Point mutations were introduced into the MS-AP-1, ZIIIA, and
ZIIIB oligonucleotides in an attempt to establish which base
pairs mediate specific DNA binding by ZEBRA and Fos-GCN4.
The oligonucleotides created were MS-AP-1* (TTAGTCA), ZIIIA*
(TGAGCAA) and ZIIIB* (TGAGCAA).

ZIIIA* and ZIIIB* contain

an identical 7 bp core recognition site

(TGAGCAA), but

differ in their surrounding sequences (see Experimental
procedures).

Additionally, the ZIIIA and ZIIIB

oligonucleotides were mutated at 4 positions to generate the
ZIIIAm and ZIIIBm oligonucleotides.
ZEBRA bound with relatively high affinity to the MS-AP1, ZIIIA and ZIIIB sequences containing a single point
mutation (MS-AP-1*, ZIIIA*, ZIIIB*)

(Fig. 3A).

However, it

was unable to bind either the ZIIIAm or ZIIIBm sites which
contain 4 base pair changes (Fig. 3A).

The lack of binding

to the ZIIIAm or ZIIIBm sites confirms the importance of the
identified core element.

Fos-GCN4 was more fastidious in

its binding site requirements; it recognized the ZIIIB*
(TGAGCAA) sequence, but did not interact with any of the
other mutated oligonucleotides (Fig. 3B).

ZIIIA* and ZIIIB*

differ from the AP-1 consensus at 2 nucleotides, while ZIIIB
differs at 3 positions and ZIIIA differs at only one.
ZIIIA* and ZIIIB* contain the same 7 bp recognition sequence
94
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but their surrounding sequences vary.

These results suggest

that ZEBRA is considerably more tolerant of changes within
the 7 bp recognition sequence than Fos-GCN4.
Competition Analysis to Determine the Affinities of ZEBRA
and Fos—GCN4 for AP-1 and ZEBRA Promoter Sequences.

The

relative affinities of ZEBRA and Fos-GCN4 for AP-1 related
sequences were assayed by competition analysis (Fig. 4).
Complex formation between ZEBRA or Fos-GCN4 and the MS-AP-1
probe were assayed in the presence of three concentrations
of cold competitor oligonucleotides.

The relative reduction

of AP-1 complex formation is proportional to the affinity of
ZEBRA or Fos-GCN4 for the oligonucleotide competitor.
Disruption was quantified by comparing the integrated
intensity of each shifted complex as a function of the
concentration of oligonucleotide competitor (Figs. 4C and
D) .

The ZEBRA complex formed with the MS-AP-1 site was most

efficiently competed with MS-AP-1, ZIIIA*, and ZIIIB* (Figs.
4A and 4C).

A 5 fold molar excess of these oligonucleotides

eliminated ZEBRA binding to 32P labelled MS-AP-1, whereas a
50 fold molar excess of ZIIIA, ZIIIB, or Double
oligonucleotide was required to achieve a similar level of
inhibition (Figs. 4A and C).

The ZEBRA/MS-AP-1 complex was

minimally reduced by the addition of a 50 fold molar excess
of Z-AP-1 octamer and was not affected by the addition of
unlabeled ZIIIAm, ZIIIBm, or a control oligonucleotide with
no AP-1 like sequences (Figs. 4A, 4C and data not shown).
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Thus, ZEBRA, binds with highest affinity to TGAGTCA (MS-AP-1)
and TGAGCAA (ZIIIA* and ZIIIB*) sites and with a lower
affinity to TTAGCAA (ZIIIB), TGAGCCA (ZIIIA), TTAGTCA (MSAP-1*) , and the Double oligonucleotide (Figs. 4C and 5).
The Fos-GCN4/MS-AP-1 complex was efficiently competed
with a 5 fold molar excess of Z-AP-1 octamer, 20 fold excess
of MS-AP-1 or a 50 fold molar excess of ZIIIB* (Figs. 4B and
4D).

Suprisingly, the Double oligonucleotide which was

bound by Fos-GCN4 in a gel retardation assay was unable to
disrupt the formation of a complex at the MS-AP-1 site
(Figs. 2, 4B and 4D).

None of the remaining divergent AP-1

sites competed with the formation of a Fos-GCN4/MS-AP-l at a
50 fold molar excess (data not shown).

A second competition

experiment was also quantified; the relative affinities of
ZEBRA and Fos for the various oligonucleotides was found to
be the same in both experiments (data not shown).
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DISCUSSION
Binding Site Specificities of ZEBRA and Fos-GCN4.

ZEBRA and

Fos bind similar DNA sequences, and both ZEBRA expression
and TPA treatment result in activation of EBV lytic viral
DNA replication (Chevallier-Greco et al., 1986, Countryman
and Miller, 1985, Gradoville et al., 1990, Taylor et al.,
1989, zur Hausen et al., 1978).

An underlying biological

question is whether Fos, or other cellular AP-1 proteins,
mediate TPA induction of the EBV lytic cycle.

While this

question has not been addressed directly, I have begun by
assessing the binding affinities of ZEBRA and Fos-GCN4 for
several sites in the BZLF1 and MS-EA promoters.

I chose to

compare ZEBRA binding to that of Fos-GCN4 since the first
indication that ZEBRA was a DNA binding transactivator came
from a recognition of the homology between the basic domains
of ZEBRA and c-fos (Farrell et al., 1989).
generally binds in-vivo

Although Fos

as a Fos/Jun heterodimer, an

artificial Fos-GCN4 construct, containing the Fos basic
domain fused to the GCN4 leucine zipper, was used in order
to allow Fos to bind DNA as a homodimer.

Many groups have

previously shown that that the target site specificity of a
protein is not affected by the nature of its leucine zipper
(Kouzarides and Ziff, 1989, Nakabeppu and Nathans, 1989,
Neuberg et al., 1989a and Sellers and Struhl, 1989).
ZEBRA bound a much broader range of DNA sequences
than did Fos-GCN4 (Fig. 2).

ZEBRA bound the palindromic AP97
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1 site, but also bound the ZIIIA and ZIIIB sites which do
not contain perfect dyads.

Unexpectedly, oligonucleotides

with base pair substitutions which disrupt the partial dyad
nature of ZIIIA or ZIIIB (TGAGCCA to TGAGCAA or TTAGCAA to
TGAGCAA) were bound by ZEBRA with increased affinity (Fig.
3, Fig. 5).

This departs from the proposed "scissors-grip"

model of DNA binding by dimeric proteins, in which each
protein monomer is hypothesized to bind an identical DNA
"half-site" (Vinson et al., 1989).

Although it is known

that ZEBRA (expressed in vitro or as a trpE fusion protein)
binds DNA as a homodimer (Chang et al., 1990, Flemington and
Speck, 1990c, Kolman et al., 1991, Lieberman and Berk, 1990,
Taylor et al., 1991b), it is unclear whether both monomers
contact or recognize symmetrical units on DNA.

There are

two possibilities which could explain ZEBRA binding to
assymetric sites: first, only one subunit of the ZEBRA
homodimer contacts DNA; or second, each subunit recognizes a
wide variety of half-site sequences, thereby recognizing
asymmetric sequences.

Our preliminary data suggests that

the second hypothesis accounts for ZEBRA'S asymmetrical
recognition of DNA (Kolman et al., 1991, Taylor et al.,
1991b).

It has also been found that the homodimeric

glucocorticoid receptor binds DNA asymmetrically and is more
sensitive to mutations in the right half of its binding site
(reviewed in Beato, 1989).
Fos-GCN4 binds as a homodimer to the palindromic AP-1
98
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site (Hope and Struhl, 1987, Kouzarides and Siff, 1989,
Sellers and Struhl, 1989, Fig. 1).

Both Fos/Jun

heterodimers and artificial Fos homodimers have been shown
to recognize the AP-1 consensus sequence asymmetrically
(Risse et al., 1989).

This suggests that the Fos basic

domains in a homodimer interact with heptamer target
sequences in a manner equivalent to a Fos/Jun heterodimer. A
Fos-GCN4 homodimer did not bind any of the divergent AP-1
sites with high affinity.

It was unable to recognize ZIIIA,

ZIIIB, or ZIIIA*, all of which were recognized by ZEBRA
homodimers (Figs. 2 and 5).

Fos-GCN4 bound ZIIIB* (TGAGCAA)

but not ZIIIA* even though both oligonucleotides contain the
same heptamer core sequence.

This result suggests that

flanking nucleotides influence binding ability.

ZIIIB*, but

not ZIIIA*, contains the bases CA and TG adjacent to the
recognition sequence increasing the dyad symmetry of the
site, CATGAGCAATG.

The importance of flanking sequences in

the binding affinity of Fos was noted by Nakabeppu and
Nathans (1989).

They found that substitutions of cytosine

(C) and guanosine (G) for adenine (A) and thymine (T) bases
at flanking positions 1 and 10 of the cyclic AMP response
element resulted in greater than a 90% decrease of
homodimeric Fos or Fos/Jun binding activity (Nakabeppu and
Nathans, 1989).

This novel result indicates that the

binding site specificity of Fos is broader than originally
proposed; Fos-GCN4 can bind an asymmetric heptamer sequence
99
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with two mismatches from the AP-1 consensus in an
appropriate flanking oligonucleotide environment.
While ZEBRA has a broader specificity than Fos-GCN4 in
recognizing various heptamer sequences related to the AP-1
consensus, only Fos-GCN4 binds the Z-AP-1 octamer sequence
(TGACATCA) located in the BZLF1 promoter with high affinity.
This is interesting since this site was originally defined
as the Jun/AP-1 response element in the iun promoter and is
TPA responsive (Angel et al., 1988b).

Thus, ZEBRA is unable

to bind a subset of the known AP-l/TPA responsive elements.
Fos/Jun as well as artificial Fos homodimers are known
to bind the octamer cAMP response element (CRE)

(TGACGTCA)

which differs from Z-AP-1 octamer at the 5th position (G to
A) (Chang et al., 1990, Flemington and Speck, 199a,
Nakabeppu and Nathans, 1989, Nakabeppu et al., 1988, Risse
et al., 1989, Sellers and Struhl, 1989).

While the sites

are similar, Deutsch et al. have shown that they have
different signal-responsive properties, that is, CREs are
not responsive to TPA (Deutsch et al., 1988).

Chang et al.

have shown that ZEBRA does not bind a CRE element (Chang et
al., 1990).

Although ZEBRA does not bind the TPA responsive

Z-AP-1 octamer site, binding to this site may be important
in the induction of the EBV lytic cascade.

For example, Fos

or another cellular AP-1 protein may bind this site in vivo
(Angel et al., 1988b, Angel et al., 1987, Deutsch et al.,
1988, Lee et al., 1987) leading to low levels of transcrip100
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tion from the BZLF1 promoter.

ZEBRA, could then bind to the

ZIIIA and ZIIIB sites in the BZLF1 promoter resulting in
autoactivaton of this gene (Flemington and Speck, 1990b).
Binding of ZEBRA and Fos-GCN4 to an Oligonucleotide with Two
Binding Sites.

We studied ZEBRA and Fos-GCN4 binding to the

Double oligonucleotide in which the ZIIIA and ZIIIB
heptamers occur as they are arranged in the BZLF1 promoter:
oriented head to tail and separated by six base pairs.

Two

ZEBRA response elements, ZRE1 (TGTGTAA) and ZRE2 (TGAGCAA)
(identical to the heptamer core sequence in the ZIIIA* and
ZIIIB*), are arranged in a similar manner, separated by 10
bp in ori lyt (Lieberman et al., 1990).

This arrangement

may be a common mode of targetting ZEBRA transcriptional
control in the EBV genome.
These results show that two ZEBRA homodimers can bind
ZIIIA and ZIIIB simultaneously on the Double oligonucleotide
(Fig. 1).

We have not determined which site is filled

initially although footprinting data has demonstrated that
ZEBRA binds ZIIIB with higher affinity than ZIIIA
(Flemington et al., 1990b, Lieberman and Berk, 1990).

Gel

shift experiments with limiting dilutions of ZEBRA protein
show that both sites are bound only after a significant
portion of single sites are filled.

Furthermore,

competition experiments indicate that ZEBRA does not have a
greater affinity for the Double oligonucleotide than for
either single site (Figs. 4A and 4C).

Thus, ZEBRA binds
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non-cooperatively to these sites.

However, binding of ZEBRA

to these two adjacent sites may allow for synergistic
transactivation.
Fos—GCN4, which did not bind oligonucleotides bearing
single ZIIIA or ZIIIB sites, bound the Double
oligonucleotide (containing ZIIIA and ZIIIB) as a high
molecular weight complex (Figs. 1 & 2). The association of
this slow mobility complex can be disrupted by addition of
ZEBRA protein suggesting that the two proteins compete for a
similar sequence on the Double probe (unpublished data).
However, the Double oligonucleotide did not interfere with
Fos-GCN4/MS-AP-l complex formation (Figs. 4B and D).

One

explanation for this phenomenon is that these associations
are non-competitive because the two probes bind different
Fos-GCN4 complexes.

The MS-AP-1 probe is bound by a Fos-

GCN4 homodimer whereas the Double probe may only bind a FosGCN4 complex with more than two monomers and perhaps with
other proteins.

Alternatively, Fos-GCN4 might bind the

Double oligonucleotide indirectly through a second protein
which is not required for binding to the MS-AP-1 site.
Several groups have recently examined ZEBRA binding
activity in EBV promoters and the origin of EBV lytic
replication

(ori lyt)

(Farrell et al., 1989, Flemington and

Speck, 1990b, Hardwick et al., 1988, Kenney et al., 1988,
Lieberman and Beerk, 1990, Lieberman et al., 1990, Packham
et al., 1990, Urier et al., 1989) but there had been no
102
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studies directly comparing the ability of Fos and ZEBRA to
bind the same sites.

Since our work was completed Chang et

al. (1990) reported on the binding specificities of ZEBRA
and Fos/Jun in ori lyt.

Our work on the binding

specificities of ZEBRA and Fos for sites in the BZLF1 and
MS-EA promoters provides both complementary and novel
observations.

Chang et al . demonstrated that ZEBRA binds an

AP-1 consensus site with higher affinity than divergent
heptamer sites in ori lyt, whereas we have found that it
binds equivalently to an AP-1 site as well as a divergent
sequence (ZIIIA* or ZIIIB*)

(Chang et al., 1990).

ZIIIA*

and ZIIIB* contain the same core heptamer sequence found in
ZRE2 in ori lyt (Chang et al., 190).

The two studies show

that Fos/Jun and Fos-GCN4 are restrictive in binding
divergent AP-1 heptamer sites.

However, we have found novel

binding of a Fos-GCN4 homodimer to a divergent heptamer
sequence flanked by dyad symmetry (ZIIIB*).
The interaction of ZEBRA with cellular AP-1 sequences
may result in the displacement of Fos or other cellular AP-1
factors, thereby precluding their activity.

Alternatively,

by binding AP-1 sites, ZEBRA may transactivate (or possibly
transrepress) cellular genes in a manner analogous with
cellular AP-1 transcription factors.

AP-1 proteins are

probably not able to activate transcription of EBV genes
through ZEBRA responsive elements because at least one AP-1
binding protein, Fos-GCN4, is unable to bind those sites.
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The divergent nature of the ZEBRA responsive sites makes it
unlikely that cellular AP-1 proteins can have an ongoing
role promoting viral transcription and activating the EBV
lytic cycle.

Additionally, the ability of Fos to bind the

TPA responsive Z-AP-1 octamer and CRE sites, which are not
bound by ZEBRA, indicates that ZEBRA can not simply
substitute for Fos.

The ability of these related proteins

to bind similar as well as distinct sites adds yet another
level of complexity to the relationship of these
transactivators in regulating cellular and viral gene
expression.

104
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Figure 1.

Binding specificity of ZEBRA and Fos-GCN4 for AP-

1 and BZLF1 promoter sequences (Zp).

(A) Sequences of the

ZEBRA (BZLF1) and MS (BSLF2-BMLF1) promoters.

AP-1 like

sequences are underlined (Farrell et al., 1989, Flemington
and Speck,1990b) and the transcriptional start site of the
BZLF1 gene is marked.

(B) Gel retardation assay showing the

specificities of trpE (vector) , trpE-ZEBRA (Z1_2A5) and trpEFos-GCN4 (F0S-GCN4) proteins for oligonucleotides containing
the AP-1 and Zp sequences; Z-AP-1 octamer, ZIIIA, and ZIIIB
(Flemington and Speck, 1990b).

The Double oligonucleotide

contains sites ZIIIA and ZIIIB in the orientation found in
the BZLF1 promoter.

Equivalent amounts of bacterially

expressed fusion proteins were incubated with each
oligonucleotide (4 X 10'13M) for thirty minutes prior to
analysis of the retardation complexes by gel
electrophoresis.
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Figure 2.

Binding of ZEBRA and Fos-GCN4 to the Double

oligonucleotide.

ZEBRA and Fos-GCN4 proteins were titrated

in a gel retardation assay with

4 X 10 "13M 32P-labeled MS-

AP-1 or Double (ZIIIA + ZIIIB) probe.

Various volumes of

protein extract (shown as ul in the figure) were incubated
with the MS-AP-1 or Double probe in the presence of poly
dldC.

ZEBRA and Fos-GCN4 both bind to the MS-AP-1 site as a

single complex indicated as S.

Mobility shift complexes

with a slower mobility are indicated as D.
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Figure 3.

Gel retardation assay illustrating the binding

specificities of ZEBRA and Fos-GCN4 for mutant recognition
sequences.

MS-AP-1, ZIIIA, and ZIIIB oligonucleotides were

mutated at a single position (noted by a *); the base
substitution is underlined.

Two oligonucleotides mutated at

multiple positions are designated ZIIIAm and ZIIIBm.

The

control oligonucleotide contains no AP-1 related sequences.
Bacterially expressed trpE-ZEBRA (A) or trpE-Fos-GCN4 (B)
was incubated with these 32P-labeled oligonucleotides and
binding was analyzed by a mobility shift assay.
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Figure 4.

Competition experiment to evaluate the affinity

of ZEBRA, and Fos-GCN4 for AP-1 and ZEBRA promoter sites.

4

X 10'13M 32P- labeled MS-AP-1 oligonucleotide was incubated
with bacterially expressed trpE-ZEBRA (A) or trpE-Fos-GCN4
(B) in the presence of three concentrations of cold
competitor DNA.
electrophoresis.

Complex formation was resolved by gel
Only the shifted complexes are shown and

the nature of the competitor and its molar excess over the
MS-AP-1 probe is indicated.

(C)

These results were

quantified by scanning the relative intensity of each
shifted complex.

The percent disruption of the ZEBRA/MS-AP-

1 complex is plotted for each oligonucleotide competitor.
The stippled portion of each bar represents the percent
disruption with a 5 fold molar excess of oligonucleotide
competitor, while the shaded area represents the additional
disruption with a 20 fold molar excess of competitor.

(D)

Results were quantified as in (C) for disruption of the FosGCN4/MS-AP-1 complex.
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Figure 5. Evaluation of ZEBRA and Fos-GCN4 binding site
affinities. Affinities were determined from the competition
analysis in Fig. 4.

Nucleotide substitutions in the

recognition sequences are noted by bold type.

The relative

affinities are marked with 1 representing the highest
affinity while a dash (-) indicates that the protein did not
bind the sequence specifically.
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CHAPTER V

THE UNIQUE DNA BINDING ACTIVITY OP ZEBRA IS INHIBITED
BY CASEIN KINASE II PHOSHPORYLATION

INTRODUCTION
I have recently studied the DNA binding activity of the
Epstein-Barr viral replication activator, ZEBRA (Taylor et
al., 1991a).

This protein has sequence homology to the

Fos/Jun family in its basic domain (exon II) and shares the
ability of these proteins to bind an AP-1 consensus site
(Farrell et al., 1989).

However, ZEBRA is also able to bind

divergent AP-1 sites not bound by Fos or Jun (Chang et al.,
1990, Flemington and Speck, 1990b, Lieberman et al., 1990,
Packham et al., 1990, Taylor et al., 1991, Urier et al.,
1989) .
Both ZEBRA and Fos contain potential casein kinase II
(CKII) phosphorylation sites directly upstream of their
basic DNA binding domains (Fig. 1).

Casein kinase II is a

ubiquitous protein kinase present in both the cytoplasm and
nucleus of eukaryotic cells (Hathaway and Traugh, 1982,
Edelman et al., 1987).

Studies using synthetic peptides

have shown that CKII preferentially phosphorylates serine or
threonine residues situated 5' to clusters of acidic amino
acids (Marin et al., 1986, Kuenzel et al., 1987).

CKII also

appears to selectively phosphorylate residues adjacent to
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predicted B-turns (Hathaway and Tragh, 1982).
CKII activity is stimulated by mitogens such as serum,
TPA, insulin, insulin-like growth factor and epidermal
growth factor (Ackerman and Osheroff, 1989, Carroll and
Marshak, 1989, Carroll et al., 1988, Karlund and Czech,
1988, Sommercorn et al., 1987).

This suggests that CKII may

play a role in the regulation of cell growth.

Additionally,

it has been determined that a large number of nuclear
oncoproteins satisfy the substrate requirements for casein
kinase II (CKII) phosporylation (Carroll et al., 1988, Krebs
et al., 1988).

The SV40 large T antigen, P53 tumor

suppressor protein, HPV E7 oncoprotein, c-Myc, c-Myb and
serum response factor (SRF) have all been shown to be
specifically phosphorylated by CKII (Barbosa et al., 1990,
Carroll et al., 1988, Grasser et al., 1988, Krebs et al.,
1988, Luscher et al., 1990, 1989, Manak et al., 1990, Meek
et al., 1990).
While the physiological role of kinases has not been
definitively determined for any system, they have been
implicated in the regulation of various protein functions.
CKII has recently been shown to uniquely affect DNA binding
of two unrelated proteins.

CKII phosphorylation inhibits

DNA binding by the c-myb oncogene but enhances the binding
activity of the serum response factor, a factor which
mediates Fos transcription (Luscher et al., 1990, Manak et
al., 1990).

Phosphorylation of a protein with an acidic
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activator domain, such as that present in GAL4 or GCN4, has
been hypothesized to enhance transcriptional activity by
increasing net negative charge (Carroll et al., 1988, Hope
and Struhl, 1988, Ma and Ptashne, 1987, and Ptashne, 1988).
Both GAL4 and GCN4 contain potential CKII sites within the
acidic domain (Carroll et al., 1988).

Although this

hypothesis has not been proven, protein phosphorylation has
been shown to upregulate transcriptional activation of CREB
and the yeast heat shock factor as well as DNA replication
by SV40 (Sorger and Pelham, 1988, Virshup et al., 1989,
Yamamoto et al., 1988, Dwarki et al., 1990, reviewed,
Edelman et al., 1987).
Thus, it was of interest to determine whether the
potential CKII acceptor sites found within the acidic
domains of ZEBRA and the related Fos protein are
phosphorylated.

I have determined that only ZEBRA is

phosphorylated by CKII in-vitro.

Additionally, I have found

that CKII specific phosphorylation of ZEBRA results in a
reversible inhibition of DNA binding.
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RESULTS
CKII Differentially Affects ZEBRA and Fos Phosphorylation. A
TrpE-ZEBRA fusion protein as well as purified ZEBRA protein
(expressed in E.coli) were used to study the ability of CKII
to specifically phosphorylate the ZEBRA protein (Carey et
al., 1991, Taylor et al., 1991a).

These proteins were

incubated with purified CKII and [Y-32p]ATP and analyzed by
autoradiography following SDS-polyacrylamide gel
electrophoresis (Carroll et al., 1988, Carroll and Marshak,
1988). Labelled phosphate was transferred to a casein
substrate as well as to the TrpE-ZEBRA and purified ZEBRA
proteins (Fig. 2).

However, a control E. coli extract with

trpE protein was not phosphorylated by CKII (Fig. 2).
Additionally, labeled phosphate was not incorporated in the
\/
ZEBRA protein when [.<- P]ATP was added without CKII (data
not shown).
Since ZEBRA has been hypothesized to be related to the
Fos oncogene protein and the two proteins have related DNA
binding specificities, we were interested in determining
whether the two proteins may be similarly modified by kinase
activity.

Both proteins contain potential CKII sites in

similar positions, directly 5# to the basic DNA binding
domain (Fig. 1) (Carroll et al., 1988, Farrell et al., 1989,
Taylor et al., 1991a).

CKII phosphorylation of a trpE-Fos-

GCN4 fusion protein was studied.

This fusion protein

contains the basic DNA binding domain of Fos (aa 126-162,
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which includes the potential CKII phosphorylation site)
fused in frame to the GCN4 leucine zipper.

It has

previously been shown that the GCN4 leucine zipper does not
affect the binding specificity of the Fos protein but allows
it to bind DNA as a homodimer (Abate et al., 1990,
Kouzarides and Ziff, 1989, Nakabeppu and Nathans, 1989,
Sellers and Struhl, 1989).

Unlike ZEBRA, this protein was

not phosphorylated by CKII (Fig. 3).

Additionally, a TrpE-

Fos fusion protein containing only Fos amino acids 12 6-162
was not phosphorylated (data not shown).
Happing the CKII Specific Phosphorylation Sites in ZEBRA.

A

panel of ZEBRA deletion mutants were utilized to map the
CKII specific phosphorylation sites (Taylor et al., 1991a).
These proteins, which were all expressed as TrpE fusion
proteins in E. coli. were incubated with purified CKII plus
[\^-32P]ATP and analyzed by autoradiography following
polyacrylamide electrophoresis (Fig. 3, Taylor et al.,
1991).

The smallest ZEBRA deletion proteins which could be

phosphorylated by CKII were Z141_245, Z4111_159, Z^.^, and Z168_202
localizing the CKII phosphorylation region to amino acids
.160-198 (Fig. 3 and data not shown) .

The two serines which

are potentially phosphorylated in this region are S-167 and
S—173 (refer to Fig. 1).

Although the ZEBRA deletion

protein, Z172_245, was not phosphorylated in this assay, Z168_202
was a substrate, suggesting that S-173 is an acceptor site
for CKII phosphorylation but requires a few of the upstream
120

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

acidic residues for its phosphorylation.

S-167, if it were

an acceptor site, would not be expected to be phosphorylated
in the ZEBRA deletion mutant WZ,.^.

CKII phosphorylation

requires the presence of acidic residues downstream of the
acceptor site (i.e. aa 168-176) not present in this
construct (Fig. 3) (Marin et al., 1986, Kuenzel et al.,
1987) .
CKII Phosphorylation Inhibits ZEBRA Specific DNA Binding.
ZEBRA has previously been shown to bind a consensus AP-1
sequence as well as divergent heptamer sites (Chang et al.,
1990, Farrell et al., 1989, Flemington and Speck, 1990b,
Liberman et al., 1990, Packham et al., 1990, Taylor et al.,
1991a, Urier et al., 1989).

We analyzed the effects of CKII

phosphorylation on ZEBRA'S ability to bind AP-1 as well as
divergent sites.

Purified ZEBRA protein was preincubated

with CKII and ATP and then exposed to the 32P-labeled AP-1
oligonucleotide probe.

DNA binding was assayed by

determining the level of retarded complex in a mobility
shift gel.

Untreated ZEBRA protein bound the AP-1

oligonucleotide with high affinity as did ZEBRA extracts
preincubated with only CKII or ATP (Fig. 4).

However,

binding to the AP-1 oligonucleotide was almost completely
inhibited when ZEBRA protein was preincubated with both ATP
and CKII (Fig. 4).

CKII phosphorylation also inhibited

ZEBRA binding to divergent AP-1 sites located in the ZEBRA
promoter (ZIIIA, ZIIIB, and AP-l-octamer)

(data not shown,
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refer to Experimental Procedures or Taylor et al., 1991, for
sequences of oligonucleotides).
It has previously been shown that protein phosphatase
2A (PP2A) can reverse CKII phosphorylation (Luscher et al.,
1990, reviewed Cohen and Cohen, 1989).
a 15 minute

Therefore, following

preincubation of ZEBRA with ATP and CKII,

extracts were treated with PP2A for an additional 15
minutes. When ZEBRA from these extracts was analyzed for DNA
binding activity, a partial recovery of DNA binding activity
was obtained (Fig.4).

This result suggests that

phosphorylation of the ZEBRA protein does not irreversibly
inhibit its DNA binding activity.
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DISCUSSION
CKII Phosphorylation of ZEBRA.

We have demonstrated that

ZEBRA serves as a substrate for CKII phosphorylation invitro.

ZEBRA contains two potential CKII acceptor sites at

serine-167 and serine-173.

ZEBRA deletion mutants have been

used to show that these serines are contained within the
region phosphorylated by CKII (aal60-198).

The data

presented here suggest that serine-173, and possibly S-167,
are phosphorylated by CKII (Fig. 3).

Further biochemical

characterization including sequence analysis of two
dimensional phosphopeptide maps will be conducted to confirm
this result.
Although there is no data concerning the
phosphorylation state of ZEBRA in-vivo. ZEBRA was
specifically phosphorylated by CKII in-vitro.

Another

serine-threonine protein kinase, the cAMP dependent protein
kinase (Slice and Taylor, 1989), was unable to phosphorylate
the ZEBRA protein in-vitro (Taylor, unpublished data).
Interestingly, the expression and activity of CKII invivo is influenced by factors which also affect ZEBRA
expression.

ZEBRA, which triggers activation of the EBV

lytic cycle, is activated by phorbol esters (zurHausen et
al., 1978, Biggin et al., 1987, Laux et al., 1988).
Similarly, CKII activity is elevated in homogenates of cells
treated with various mitogens including the phorbol ester,
TPA (Carroll et al., 1988).

Alternatively, ZEBRA may be
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phosphorylated in-vivo by the EB viral gene product, BGLF4,
which has sequence homology with other serine/threonine
kinases (Kolman, J.L. , personal communication, Smith and
Smith, 1989).
CKII Phosphorylation of Fos.

Fos, which has a potential

CKII acceptor site (Carroll et al., 1988) in a region
similar to ZEBRA, was not phosphorylated by CKII in-vitro
(Fig. 3, Curran and Marshak, personal communication).
Several potential CKII sites in c-myc were also not
phospiiorylated by CKII in-vitro (Luscher et al., 1989).
Thus, CKII phosphorylation may not be determined solely by a
protein's primary structure.
However, the c-Fos serine-133, which corresponds to S167 in ZEBRA, is also conserved in Jun (S-249) and GCN4
leucine zipper proteins.

Since this work was completed, it

has been determined that c-Jun is phosphorylated in-vitro at
S-249 as well as T-239 and S-243 by glycogen synthase kinase
3 (Boyle et al., 1991).

Protein kinase C dephosphorylation

of c-Jun at one or more of these sites resulted in increased
DNA binding (Boyle et al., 1991).

Therefore,

phosphorylation, albeit by different kinases, may similarly
affect ZEBRA and some of the related basic-leucine zipper
proteins.
Effects of CKII Phosphorylation on ZEBRA DNA Binding.

The

effects of CKII phosphorylation on DNA binding have
previously been studied for c-myb and the serum response
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factor, SRF (Luscher et al., 1990, Manak et al., 1990).
vitro

In-

DNA binding activity of SRF was enhanced by CKII

phosphorylation, while binding of c-myb was inhibited by
phosphorylation (Luscher et al., 1990, Manak et al., 1990).
We have found that ZEBRA, like c-myb, is negatively
regulated by CKII phosphorylation.

CKII phosphorylation

abrogated ZEBRA'S ability to bind all of its target DNA
sequences (Fig. 4 and data not shown).
While ZEBRA's ability to bind DNA is crucial for its
role in transactivating early EB viral genes, the potential
function of the ZEBRA protein in the late phase of lytic
replication has not yet been studied (Flemington and Speck,
1990b, Kenney et al., 1989, Packham et al, 1990, Rooney et
al., 1989, Urier et al., 1989).

Our data suggests that

ZEBRA is a very stable protein with a half life of greater
than 48 hours (Taylor and Hagmeier, unpublished results,
refer to chapter II).

Additionally, it has recently been

shown that ZEBRA associates with a late EB viral protein
(Katz et al., manuscript in preparation).

Therefore,

regulation of ZEBRA's ability to bind DNA may be required
during the late phase of EB viral replication if the protein
serves additional functions in the lytic cascade.
Effects of CKII Phosphorylation on ZEBRA Transactivation.
CKII phosphorylation has been hypothesized to increase the
level of transactivation by acidic activators by increasing
their net negative charge (Carroll et al., 1988, reviewed
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Ptashne, 1988).

Phosphorylation by protein kinase A and

other serine/threonine kinases has been shown to increase
the transcriptional activity of CREB and yeast heat shock
factor (Yamamoto et al., 1988, Sorger and Pelham, 1988).
However, it is difficult to explain how CKII
phosphorylation could increase transcriptional activation in
the case of ZEBRA or c-myb.

Since phosphorylation of these

two proteins inhibits their DNA binding activity, one would
have to invoke a model in which ZEBRA or c~myb
transactivates transcription as a DNA binding protein and/or
as a soluble factor.

It is of interest to note that v-myb

has been reported to transactivate certain promoters (e.g.,
human hsp70) in the absence of its DNA binding domain
(Klempnauer et al., 1989).

Alternatively, phosphorylated

ZEBRA may interact with a second DNA binding factor, thereby
activating transcription at novel sequence elements.

The

extent of phosphorylation of the herpes simmplex virus gene
product, ICP4, has been shown to modulate its ability to
form complexes on specific DNA sequences (Papavassiliou et
al., 1991).
The activation domains of the ZEBRA and myb proteins
have not been definitively determined.

It is possible that

they do not contain acidic activators and that CKII
phosphorylation affects DNA binding but not transactivation.
This hypothesis is presently being studied by using ZEBRA
proteins mutated at serine-167 in transactivation assays
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(Kolman,J.L. personal communication).
Effects of CKII Phosphorylation on ZEBRA Nuclear
Localization.

Recent evidence suggests that CKII

phosphorylation may also affect the relocalization of
proteins between the cytoplasm and nucleus (Rihs et al.,
1991).

Rihs and coworkers have shown that the rate of

nuclear transport of SV40 large T antigen was affected by
mutagenesis of two serines which are phosphorylated by CKII
in-vitro (Grasser et al., 1988, Rih et al., 1991).

Although

the SV40 T antigen nuclear localization signal (NLS) was
necessary and sufficient for nuclear localization, wild type
large T-antigen accumulated in the nucleus after 30 minutes
while the mutant protein required 12 hours to achieve the
same degree of partition (Rih et al., 1991).
The CKII acceptor site in SV40 large T antigen is
located 13 aa 5' to the basic NLS (Rih et al., 1991).
Potential CKII sites are located approximately 15 amino
acids upstream of many proteins harboring nuclear
localization sequences, including polyoma T, adenovirus Ela,
c-myc, p53 and c-rel (Rih et al., 1991).

Most of these

proteins have not yet been tested for CKII phosphorylation.
However,

ZEBRA fits the CKII site/NLS motif well.

The

ZEBRA NLS has recently been localized to a region within the
basic domain of the protein (Giot et al., 1991), located
immediately downstream of the CKII phosphorylation site. The
effects of CKII on the rate of nuclear transport of ZEBRA
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may be another mechanism by which phosphorylation regulates
ZEBRA'S role in the EB lytic cycle.

128

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

Figure 1. Schematic representation of ZEBRA and Fos.

(A)

Several structural domains in both proteins are indicated
potential casein kinase II phosphorylation sites in both
ZEBRA and Fos (denoted CKII); the basic domains of both
proteins; the coiled-coil domain in ZEBRA and the leucine
zipper motif in Fos. (B) Amino acid sequences of the
potential CKII phosphorylation sites and basic domain of
ZEBRA and Fos (Biggin et al., 1987, van Straaten et al.,
1983).

The serines which are possible acceptor sites for

CKII phosphorylation are indicated in bold type (S).
Conserved residues in the ZEBRA and Fos basic domains are
marked by lines (Farrell et al., 1989).
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Figure 2. Phosphorylation of ZEBRA by casein kinase I I .

ZEBRA protein purified from E. coli

(Carey et al., 1991) or

expressed as a TrpE fusion protein was incubated with CKII
in the presence of [}j-32P]ATP at 37C for 15 minutes.
Proteins were then electrophoresed on an 8% SDSpolyacrylamide gel and analyzed by autoradiography.
Phosphorylation of casein was used as a positive control and
trpE protein was used as a negative control.
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Figure 3. Mapping the casein kinase II phosphorylation site
in ZEBRA and Fos.

(A) Various ZEBRA deletion mutants were

used to map the sites phosphorylated by CKII in ZEBRA.
Total protein from bacteria which carried various TrpE-ZEBRA
deletion proteins was resolved by SDS-polyacrylamide gel
electrophoresis and stained with Coomassie brilliant blue.
(B) Protein extracts from each of the ZEBRA deletion mutants
as well as a Fos-GCN4 construct was incubated with CKII in
the presence of [^-^PjATP at 37C for 15 minutes.

Proteins

were then electrophoresed on an 8% SDS-polyacrylamide gel
and analyzed by autoradiography.

These mutants localize the

CKII phosphorylation site(s) in ZEBRA can to amino acids
160-198.

A Fos-GCN4 construct containing the potential Fos

CKII site was not phosphorylated in vitro.
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Figure 4. Phosphorylation of ZEBRA by CKII inhibits DNA
binding.

Purified ZEBRA protein was preincubated with CKII,

ATP, or CKII + ATP for 15 minutes at 37C.

Protein

phosphatase 2A (PP2A) was added for 15 minutes following
pretreatment with CKII + ATP.

All extracts were then

incubated with a 32P-labeled oligonucleotide containing the
AP-1 consensus sequence for 20 minutes at room temperature
(22C).

Complexes were electrophoresed on a 4% acrylamide

gel in 0.5X TBE.
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CHAPTER VI

CONCLUSIONS

Activation of the Latent EBV Genome.

The discovery that

ZEBRA induces lytic EB viral DNA replication suggested that
it may function as a transactivator of lytic genes
(Countryman et al., 1985, 1987, Gradoville et al., 1990,
Rooney et al., 1988, Takada et al ., 1986).

Several groups

have shown that promoters in the EB origin of lytic
replication (orilyt) and several early genes: BZLF1, BRLF1
(R), BMLF1 (MS-EA) and BMRF1 (EA-D) are responsive to ZEBRA
activation (Chavrier et al., 1989, Chevallier-Greco et al.,
1986, Flemington et al., 1990b, Gradoville et al., 1990,
Kenney et al., 1989a, Lieberman et al., 1989, Sinclair et
al., 1991, Takada et al., 1986, Urier et al., 1989).
However, ZEBRA expression is not sufficient to induce
release of infectious EB virions in Raji cells or a tightly
latenty X50-7.17 subclone (Gradoville et al., 1990, reviewed
in Miller, 1990b).

This suggests that although ZEBRA can

directly activate a group of EBV early genes, additional
factors are required for late gene expression and virion
production.
A second EBV transactivator encoded by the BRLF1 open
reading frame (termed R) has been identified (reviewed in
Hayward and Hardwick, 1991).

This protein is also expressed

early in the lytic cycle, but is incapable of inducing viral
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replication in the absence of ZEBRA (Cox et al., 1990).

The

R transactivator is encoded as a bicistronic mRNA; the
complete BRLF1 open reading frame is encoded together with
the downstream BZLF1 sequences (Biggin et al., 1987, Manet
et al., 1989).

R transactivates expression from the EBV

origin of lytic replication (orilyt), the BMLF1 early gene
promoter, the HIV-1 long terminal repeat (LTR) and
positively regulates its own expression (BRLF1 promoter)
(Chevalier-Greco et al., 1989, Cox et al., 1990,
Hammerschmidt and Sugden, 1988, Hardwick et al., 1988,
Kenney et al., 1989b, Quinlivan et al., 1990, Sinclair et
al., 1991).

Recent evidence suggests that R and Z may act

synergistically to activate transcription of a subset of EBV
early genes (Cox et al., 1990, Giot et al., 1991, Kenney et
al., 1989b).

Furthermore, R has been shown to be one of the

factors necessary for ZEBRA activation in EBV negative cells
(Kenney et al., 1989b).
Transcription of ZEBRA.

The work presented in chapter II

indicates that ZEBRA expression is differentially regulated
in standard and defective EB viruses.

Novel upstream and

downstream sequences present in het DNA are responsible for
activation of ZEBRA expression (Fig 1-2, Rooney et al.,
1988).

Two BZLF1 specific mRNAs, 3.5 Kb and 0.9 Kb, are

spontaneously expressed in cells harboring a het virus but
are only synthesized by the standard latent virus after
chemical induction (Fig 11-10, Taylor et al., 1989).
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Initiation of the two transcripts has been mapped to the
BRLF1 and BZLF1 promoters, respectively (Manet et al., 1989,
Biggin et al., 1987).

The 3.5 Kb mRNA represents the

bicistronic message encoding both the R and ZEBRA
transactivators (Fig. 11-11, Biggin et al., 1987, Manet et
al., 1989).
It is interesting to note that no novel BZLF1 mRNAs
were detected in cells (clone 5) harboring the het virus
(Fig. 11-10, 11-15).

The 0.9 Kb BZLF1 specific mRNA can be

transcribed by either the het or standard EB genome, whereas
the 3.5 Kb message can only be transcribed by the standard
virus.

The rearrangements in HR-1 clone 5 het DNA result in

a deletion of most of the BRLF1 open reading frame (refer to
Fig. I-II).

The kinetics of transcription and decay of both

mRNAs were identical in clone 5 cells (Fig. 11-15, Taylor
and Hagmeyer, unpublished data).

Thus, even when ZEBRA

expression is aberrantly regulated in the defective genome,
transcription of BRLF1 and BZLF1 are closely linked.
Coordinate expression of these two mRNAs may be mediated by
different mechanisms since Sinclair et al. (1991) recently
showed that the BZLF1 promoter is responsive to TPA while
the BRLF1 promoter is not.

Alternatively, stimulation of

transcription at both the BZLF1 and BRLF1 promoters may be
mediated by low levels of the ZEBRA transactivator
(Flemington and Speck, 1991b).

WZhet may spontaneously

produce enough het ZEBRA to activate the standard promoters
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in clone 5 cells.

TPA, on the other hand, activates

endogenous AP-1 transcription factors (Angel et al., 1987,
Lee et al., 1987) which may induce transcription of the
standard BZLF1 promoter.

ZEBRA produced in this way could

then auto-stimulate the BZLF1 promoter (0.9 Kb transcript)
and initiate transcription from the BRLF1 promoter (3.5 Kb
transcript).
In contrast to the results of Giot et al. (1991), I did
not observe a decreased level of transcription of the BRLF1
and BZLF1 bicistronic mRNA when ZEBRA was expressed
spontaneously from the het genome (Fig. 11-10).

The

importance of the R transactivator in regulating induction
of the EBV lytic cycle awaits the development of a system
for recovering mutant viral genomes.
ZEBRA DNA Binding. DNA binding is often required for
transcriptional activation by transactivators.

The

demonstration that ZEBRA shares homology with members of the
cFos family (Farrell et al., 1989) suggested that it may
bind a consensus AP-1 site and activate promoters which
carry a copy of this sequence.

Indeed, ZEBRA has been shown

to transactivate the c-fos promoter in a chloramphenicol
acetyl transferase (CAT) assay although it was unable to
activate the c-jun promoter (Flemington and Speck, 1990d).
Furthermore, AP-1 transactivators may regulate ZEBRA
expression via an AP-1 octamer sequence located in the BZLF1
promoter (refer to chapter III, Flemington and Speck, 1990b,
140

R eproduced with perm ission o f the copyright owner. F urther reproduction prohibited w itho ut perm ission.

Taylor et al., 199a).

This finding suggests that ZEBRA, and

some AP-1 proteins may function together to regulate
induction of the lytic cycle.
ZEBRA directly binds an array of related DNA motifs
including a consensus heptamer AP-1 sequence (refer to
chapter III, Chang et al., 1990, Farrell et al., 1989,
Flemington and Speck, 1990b, Packham et al., 1990, Lieberman
and Berk, 1990, Lieberman et al., 1990, Taylor et al.,
1991a, Urier et al., 1989). The various EBV genes which were
found to be transactivated by ZEBRA, including BZLF1, BRLF1,
orilyt, BMRF1 and BMLF1, all contain ZEBRA binding sites in
their promoters (Chang et al., 1990, Farrell et al., 1989,
Flemington and Speck, 1990b, Kenney et al., 1989b, Packham
et al., 1990, Lieberman and Berk, 1990, Lieberman et al.,
1990, Sinclair et al., 1991, Taylor et al.,
al., 1989).

1991a, Urier et

Although many of the ZEBRA binding sites do not

contain a dyad symmetry, ZEBRA binds DNA as a dimer and
requires two intact basic domains for DNA binding activity
(refer to chapter III, Chang et al., 1990, Kolman et al.,
1991, Taylor et al., 1991a, 1991b).
Regulating ZEBRA DNA binding activity.

Regulation of ZEBRA

DNA binding activity may be important in the EBV lytic
cycle.

It has recently been shown that DNA binding activity

can be regulated by phosphorylation, redox potential and
dimerization (refer to chapter V, Abate et al., 1990b, Boyle
et al., 1991, Luscher et al., 1990, Manak et al., 1990, Sun
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and Baltimore, 1991).

Additionally, phosphorylation of an

inhibitory protein, termed IP-1, inhibits DNA binding of
Fos-Jun heterodimers (Auwerx and Sassone-Corsi, 1991) .
ZEBRA, but not the related Fos protein, can be
phosphorylated in-vitro by casein kinase II (CKII).

ZEBRA

phosphorylation results in an abrogation of its DNA binding
activity to all target sequences (refer to chapter V ) .
Abate and co-workers have found that DNA binding of
Fos-Jun heterodimers is modulated by a reduction-oxidation
of a single conserved cysteine in the basic DNA-binding
domains of the two proteins (Abate et al., 199ob).

This

cysteine is conserved in the basic domain of ZEBRA, and as
is the case for Fos-Jun heterodimers, ZEBRA is unable to
bind DNA in the absence of a
N., unpublished data).

reducing agent (DTT) (Taylor,

Thus, regulation of the redox or

phosphorylation state of ZEBRA (or a related regulatory
protein) may influence ZEBRA DNA binding activity in-vivo.
Regulation of the dimerization potential of leucine
zipper and helix-loop-helix (HLH) proteins is important for
DNA binding activity and specificity.

As discussed in

chapter IV, DNA binding of basic-leucine zipper (bzip)
proteins is regulated by dimerization potential.

A GCN4

leucine zipper homodimerizes whereas a fos zipper dimerizes
specifically with jun and jun dimerizes with itself or fos
(Kouzarides and Ziff, 1989, Neuberg et al., 1989, Sellers
and Struhl, 1989, Nakabeppu and Nathans, 1989).

The binding
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specificities of these proteins is also modulated by
dimerization (Benbrook and Jones, 1990, Gounari et al.,
1990, Kara et al., 1990, Ivashkiv et al., 1990).
Additionally, the E12 bHLH protein can form homo-or
heterodimers, but only binds DNA as a heterodimer and the
myc bHLH-zip protein only binds DNA as a heterodimer
(Blackwood and Eisenman, 1991, Sun and Baltimore, 1991).
ZEBRA, which dimerizes via a coiled-coil interaction
(Flemington and Speck, 1990c), homodimerizes and fails to
interact with the leucine zipper domains of GCN4 or jun
(refer to chapter III, Chang et al., 1990, Kolman et al.,
1991, Taylor et al., 1991b).

Target proteins which

heterodimerize with ZEBRA, thereby regulating DNA binding
activity and transactivation, may be identified by screening
cDNA expression libraries.

One candidate for

heterodimerization is the human heat shock protein, hsp70,
which shares homology with ZEBRA at amino acid positions
important for the formation of a coiled-coil (Kolman, J.L.,
personal communication).

Additionally, ZEBRA associates

with a late EB viral protein which may modify its activity
(Katz et al., manuscript in preparation).
Regulation of ZEBRA activity.

ZEBRA transactivation is

regulated by EBV and cellular factors: ZEBRA activation of
orilyt, BRLF1, BMRF1 and BMLF1 is enhanced by an interaction
with R; ZEBRA acts synergistically with the HIV-1 tat
transactivator to activate the HIV-1 LTR; and ZEBRA acts
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synergistically with c-myb to activate the BMRF1 and SV40
early promoters (Chevallier-Greco et al., 1989, HolleyGuthrie et al., 1990, Kenney et al., 1989a, manuscript
submitted, Lieberman et al., 1988, Mallon et al., 1990,
Sinclair et al., 1991).

Although the importance of these

various factors in regulating ZEBRA activity in-vivo has not
yet been determined, these results suggest that interactions
with cellular and viral transcription factors are required
for disruption of EBV latency.
The properties of monomer proteins determines the
transactivation activities of Fos/Jun heterodimers (Chiu et
al., 1989, Nakabeppu and Nathans, 1991, Schutte et al.,
1989).

Heterodimers of c-Fos or c-Jun with Jun-B or a

naturally truncated form of FosB, respectively, are
transactivation deficient (Schutte et al., 1989, Nakabeppu
and Nathans, 1991).

A truncated BZLF1 cDNA containing BRLF1

sequences fused to 3' exon I sequences of BZLF1 has been
identified (Manet et al., 1989).

While the function of this

protein has not been determined, it may heterodimerize with
ZEBRA and thus, alter its target recognition sequence or
transactivation potential.
Several groups have recently attempted to map the ZEBRA
activation domain (Baumann et al., manuscript in
preparation, Carey et al., manuscript in preparation, Giot
et al., 1991, Rooney et al., 1990).

It is generally agreed

that the activation domain is encoded by exon I of ZEBRA but
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there is some disagreement as to the precise amino acids
responsible for activation.

Additionally, Baumann and

colleagues have found that the ZEBRA transactivation domain
may be distinct from a second domain required for disruption
of EBV latency (Baumann et al., manuscript in preparation).
Thus, the process by which ZEBRA and associated proteins
induce the EBV lytic cycle promises to be complex.
The role of EBV replication in disease. Activation of EBV
has been observed in oral hairy leukoplakia, an AIDs
associated lesion (Greenspan et al., 1985).

Defective viral

DNA containing a rearrangement of BamHI W to BamHI Z
sequences, similar to the recombination found in P3HR-1, has
been identified in 2 of 10 oral hairy leukoplakia lesions
(Patton et al., 1990).

Furthermore, antibodies to ZEBRA as

well as spontaneous lytic EB viral DNA replication are found
in AIDS patients, but not in control individuals.

These

data suggest that activation of ZEBRA (by recombination or
other processes) is important in the pathogenesis of OHL
(Alsip et al., 1988, Patton et al., 1990, Joab et al.,
1991).

The mechanisms by which ZEBRA expression is

suppressed and activated in-vivo may remain an enigma for a
few more years.
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EXPERIMENTAL PROCEDURES

Cell Lines
HH514-16 (clone 16) is a prototypic HR-1 subclone which
contains standard Epstein-Barr virus but lacks het virus.
Clone HH543-5 (clone 5) harbors hypermolar levels of het DNA
in addition to standard EB virus (Rabson et al., 1982).

The

B95-8 cell line is a marmoset cell line derived by
cocultivation of marmoset cells with a human lymphoblastoid
cell line (Miller et al., 1982).

These cell lines were

grown in RPMI 1640 with 8% fetal calf serum, penicillin,
amphotericin B (Fungizone) and streptomycin.
COS-1 cells were grown in Dulbecco modified Eagle
medium with 8% fetal bovine serum.
Chemical Induction and Inhibition
HR-1 cells were induced with sodium butyrate (3 mM) or
TPA (20 ng/ml).

In some experiments, induction was

accompanied by inhibition of viral DNA replication with 100
ug of phosphonoacetic acid (PAA) per ml (Summers and Klein,
1976).
Transcription and translation were inhibited with 5 ug/ml
actinomycin or 10 ug/ml cyclohexamide, respectively.
Transfections
COS-1 cells were transfected by the DEAE-dextran
method, followed by chloroquine treatment (Luthman and
Magnusson, 1983).

COS-1 cells were seeded at a 1:5 split
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ratio in 100-mm dishes 72 hours prior to transfection.

The

medium was removed and the cells were incubated with 10 ug
of plasmid DNA and 300 ug DEAE-dextran suspended in TS
(0.14M NaCl, 0.005M KC1, 0.7M Na2HP04, 0.025M Tris HC1,
0.002M MgCl2, 0.002M CaCl2, pH 7.4) for 60 minutes at 37C in
5% C02.

The cells were washed once with TS and were then

resuspended in DMEM with 5% FCS containing 100 um
chloroquine (Sigma).

Following a 4 hour incubation, the

medium was replaced with DMEM plus 5% FCS and incubation
continued for 72 hours.
Cells used for immunoflourescence were seeded in 60-mm
dishes containing coverslips.

Transfections were carried

out as described above.
Plasmids
PSV2neo plasmids containing either WZhet (the het BamHI
fragment from defective EBV containing the BZLF1 open
reeading frame) or the standard BamHI Z fragment from EBV
FF41 or HR-1 have been described by Countryman et al.
(1987) .

A 679 bp Nael-PvuII fragment encompassing the

unspliced BZLF1 open reading frame, WZ.,_167, (including exon I
and 41 amino acids from the first intron) was isolated from
WZhet.

The overhanging end produced by PvuII digestion was

filled in with the Klenow fragment of DNA polymerase and
deoxynucleotide triphosphates.

The fragment was inserted

into the unique Smal site of the trpE bacterial expression
bector pATH 11, which was the gift of T.J. Koerner via M.
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Carlson (Taylor et al., 1989, Dieckmann and Tzagaloff,
1985) .

Deletion mutants of WZV167(+41) were constructed as

follows: WZ^gg was cloned by excision of the Hindlll
fragment of WZ.,_167(+41); WZ 133-167(+41) was cloned as a SmalHindlll fragment into pATH 10; and WZ133_167(+4) was cloned as a
SmaI-Sau3A fragment into pATH 10.
The full length BZLF1 cDNA (aal-aa245)

(Manet et al.,

1989) was cloned as a Nael-BamHI fragment into the SxnalBamHI sites of pATH 11.
Sergeant.

The BZLF1 cDNA was the gift of A.

BZLF1 deletion mutants were constructed as

follows: Zl41_245 was cloned as a Nhel-BamHI fragment, Z172_245
was cloned by deletion of sequences upstream of an internal
BsmI site in Z,,_245, Z,.^ was cloned as a Nael-PstI fragment,
and Z1m227 was cloned from a B95-8 ZEBRA cDNA (Farrell et al.,
1989) as a BamHI-HincII fragment.

All fragments were cloned

into the appropriate sites of pATH vectors.

Z2jno-i59 was

constructed by R. Baumann following BAL31 digestion of Z,.^
at the unique Nhel site (aa 141).

The 2nd exon of BZLF1,

z167-202' was d o n e d from genomic BamHI Z as a PvuII-HincII
fragment.
Mutant ZEBRA proteins were constructed by E. Flemington
using site directed mutagenesis.

The BZLF1 open reading

frame cloned in SP64 was the gift of P. Farrell (Farrell et
al., 1989).

A Hindlll -EcoRI fragment containing aa88-245

was cloned into the XhoI-EcoRI sites of pBluescript KS
(Stratagene).

Amino acids 178-180 and 187-189 were then
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mutated from KRY to EEL and RKC to EES, respectively, in two
additional constructs.

Site directed mutagenesis was

performed as described by the manufacturer (BioRad).
A trpE Fos-GCN4 chimera was constructed by John Kolman.
The fos basic domain (aa 126-162) was fused to the GCN4
leucine zipper

(aa 251-281) at an introduced Xhol site.

This

construct was the kind gift of T. Kouzarides and E.

Ziff

(Kouzarides & Ziff, 1989).

into

the BamHI and Xbal sites of the pATH 1 trpE expression

This clone was inserted

vector and is termed Fos-GCN4 or FG, fos basic domain (F)
fused to a GCN4 leucine zipper (G).

The inserts were

sequenced by John Kolman using the Sanger dideoxynucleotide
protocol modified for use with double stranded DNA clones.
Expression of TrpE-Fusion Proteins
TrpE fusion proteins were expressed as described
previously (Kleid et al., 1981).

Escherichia coli AG1

containing the various TrpE-fusion proteins were grown
overnight in LB.

The cells were then diluted 1:10 in M9

medium containing 1% Casamino Acids (Difco Laboratories,
Detroit, Mich.) and 100 ug/ml of ampicillin.

Cells were

induced for four hours with 20 ug/ml of indoleacrylic acid
after having reached an optical density of 0.2 at 600 nm.
Bacteria were pelleted and stored at -20C.
Fusion protein was enriched by preparation of an
insoluble protein fraction (Kleid et al., 1981, Klempnauer
and Sippel, 1987).

One hundred ml of bacteria were pelled
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and resuspended in 10 ml

TEN (lOmM Tris, pH 7.8; lmM EDTA;

50mM NaCl) with 1 mg/ml lysozyme.

220 ul Nonidet P-40

(NP40) was added after 15 min and incubation continued for
10 min on ice.

15 ml of a Nacl-Mg solution (1.5M NaCl; 12

mM MgCl2) containing 100 ul of 2 mg/ml DNAse was added and
the sample was nutated at 4C for one hour.

Insoluble

material was washed twice with TEN.
Fusion protein was either resuspended in SDS-sample
buffer for gel electrophoresis or dissolved in 6m urea for
DNA binding reactions.

Proteins used for DNA binding

reactions were first visualized by SDS-polyacrylamide gel
electrophoresis and stained with Coomassie brilliant blue in
order to approximate the level of induced fusion protein in
each preparation.

The volume of cells containing equivalent

amount of fusion protein (3.5 to 5 mis) were pelleted and
resuspended in 1 ml of 6m urea (Angel et al., 1988a).
were sonicated twice for 20 s each.

Cells

The urea solubilized

protein fraction was dialyzed three times for 45 min at 4C
against 15mM Hepes, pH 7.9; 75mM KC1; 0.2mM EDTA; lmM DTT
and 7.5% glycerol.

In some heterodimer experiments,

equivalent amounts of two fusion proteins were solubilized
together in urea prior to dialysis.
Tmmnni

nations

TrpE-WZ.,_167(+41) (ZEBRA exon I) fusion protein expressed
from 50 ml of cells was recovered in the insoluble protein
fraction and electrophoresed on an 8% preparative SDS150
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polyacrylamide gel.

The gel was stained with Coomassie

brilliant blue and strips containing the fusion protein were
ground and emulsified in complete Freund adjuvant (0.5 ml
per rabbit).

Rabbits were immunized by subcutaneous

injection and boosted every 2 weeks with an equivalent
amount of protein (approximately 25 mg) emulsified in
incomplete Freund adjuvant (0.5 ml per rabbit). Serum was
collected 1-2 weeks following each boost (Taylor et al.,
1989).
Tmmunofiuorescence
Following transfections on coverslips for 72 hours,
coverslips were air-dried, fixed in a 2:1 acetone:methanol
solution

and stored at -20C prior to use.

The coverslips

were incubated for 1 hour at 37C with a 1:50 dilution of
ZEBRA specific antibody in PBS++ (PBS plus lmM CaCl2 and
0.5mM MgCl2) .

Coverslips were washed with PBS++ for 10

minutes and then incubated with a 1:50 dilutin of a
rhodamine-conjugated anti-rabbit immunoglobulin for an
additional 1 hour at 37C.

Final washes were in PBS++ for 2

minutes (X5) followed by an H20 rinse.

Coverslips were

inverted and mounted in buffered glycerol (90% glycerol
buffered with 0.4M Na-bicarbonate, pH9.5) on standard
microscope slides.
Protein Electrophoresis and Western Blotting
Proteins were electrophoresed by the method of Laemmli
(Laemmli, 1970).

Protein samples were suspended in sample
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buffer (200 mM Tris, pH 6.8; 15% 2-mercaptoethanol; 1% SDS;
30% glycerol; 0.002% bromophenol blue).

Mammalian cell

extracts were sonicated for 20s and all samples were heated
at 100C for 5 minutes.

Samples were electrophoresed in a

discontinuous buffer system using vertical slab
electrophoresis at 200 volts.

The stacking gels were 4%

acrylamide (30:0.8 polyacrylamide:bis-acrylamide) in 0.125M
Tris pH 6.8 and the resolving gels were typically 8%
polyacrylamide in 0.375M Tris pH 8.8.
Proteins were either detected directly by staining or
were transferred to nitrocellulose for immunoblotting.
Proteins were directly stained with Coomassie brilliant blue
(0.1% Coomassie brilliant blue in 30% methanol and 10%
glacial acetic acid) and destained with 30% methanol, 10%
acetic acid.
Alternatively, proteins were electrotransferred to
nitrocellulose filters in 0.25M Tris, 0.15M glycine, 0.1%
SDS, and 25% methanol using a Bio-Rad transblot apparatus
for 2 hours at 200 mAmps at 4C (Towbin et al., 1971,
Burnette et al., 1981).

Nitrocellulose filters were blocked

in Blotto (5% non-fat dry milk, 10‘4% anti-foam A (Sigma) ,
0.5 uM thimerisol) at room temperature for 1-12 hours with
gentle agitation (Johnson et al., 1984).

The filters were

nutated for 1 hour in Blotto with 1:100 to 1:1000 dilutions
of a ZEBRA-specific rabbit antibody or a polyvalent human
serum, RM, which detects latent EBV proteins as well as a
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p21 late viral protein (Rowe et al., 1987).

Filters were

washed twice for 20 minutes in TS (10 mM Tris, pH 7.4; 0.9%
NaCl; 0.05% Tween-20) and incubated with a 1:2,000 dilution
of 125I-labelled staphylococcal protein A (0.5-1.0 uCi)
(Amersham) in Blotto for 60-90 minutes.

Filters were then

further washed in TS, dried and exposed to Kodak XAR-5 or
BB-5 films with intensifying screens.
Protein Phosphorylations
Purified ZEBRA protein as well as fusion proteins were
phosphorylated in casein kinase buffer (75mM KC1; 5 mM
MgCl2; 10 mM Hepes, pH 7.9; 1 mM EGTA and 0.5mM DTT).
Fusion proteins (100 ng, 2 ul) were made as described above
while ZEBRA protein (250 ng) was purified by ammonium
sulfate precipitation following overexpression in E. coli
using the tac expression vector pRW76.

The protein was 90%

pure as judged by coomasie blue staining of SDSpolyacrylamide gels (Carey et al., manuscript submitted).
Proteins were phosphorylated in the presence of lOuCi of [^32P] ATP and 5 ul of CKII.

Following incubation at 37C for

15 minutes samples were denatured by boiling and
electrophoresed on an 8% SDS-polyacrylamide gel as described
above.
Radiolabeled DNA
Purified DNA fragment probes for northern blot analysis were
electroeluted from TBE-polyacrylamide gels and radiolabelled
by the random primer method (Feinberg and Vogelstein, 1983).
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DNA fragments which were used as probes are as follows: the
5' BamHI-Hindlll fragment of WZhet mutant 80 which contains
264 bp upstream of BZLF1 and 259 bp of the first BZLF1
coding exon; a 395 bp fragment from the Hindlll site in
BZLF1 encoding the 3 1 region of exon I; a 627 bp BamHI-PstI
fragment from the BZLF1 cDNA which encodes exons I and II;
and a 538 bp SacI-BamHI fragment which is specific for the
BRLF1 open reading frame.

Typically, 100 ng of double

stranded DNA was denatured by incubation at 100C for 5
minutes in the presence of random hexamers (Pharmacia) and
then cooled on ice for 5 minutes.

The DNA was then labelled

with 33 uCi of 32P-dCTP (Amersham) and 5 units of the Klenow
fragment of E. coli DNA polymerase in Klenow buffer (50 mM
Tris-HCl, pH 7.2; 10 mM MgS04, 0.1 mM DTT, 50 ug /ml bovine
serum albumin) containing 3 uM unlabelled dATP, dGTP, and
dTTP.

Reactions were incubated at room temperature for

several hours.

DNA probes for south-western analysis were

prepared by nick translation (Rigby et al., 1977).

DNA (100

ng) was incubated for 90 minutes at 15C in Klenow buffer
with 1.25 ng of DNAse (Worthington) and 10 units of E. coli
DNA polymerase 1 (New England Biolabs) containing 3 uM
unlabelled dATP, dGTP, and dTTP and 33 uCi of 32P-dCTP.
Oligonucleotides were end-labelled in Klenow buffer in the
presence of 5 units of Klenow and 32P-labelled
deoxynucleotides for 30 minutes at room temperature.

DNA

fragment probes were purified from unincorporated label
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using G-50 sephadex columns while oligonucleotide probes
were purified over G-4 columns.
Northern Blots
Total cellular RNA or cytoplasmic RNA was harvested
from uninduced cells and at various times following
induction.

Total RNA was isolated by the guanidium

isothiocyanate method essentially as described by Chirgwin
et al. (1979).

Approximately 5 X 107 cells were resuspended

in ice cold GIT (4M guanidine isothiocyanate; 0.025M NaOAC,
pH 6.0; 1.5M B-mercaptoethanol) and layered on top of 4 ml
cesium chloride buffer (5.7M CsCl; 0.0125M NaOAC, pH 6.0) in
an SW41 polyallomer tube.

Tubes were filled completely with

GIT and centrifuged in an SW41 rotor at 32,000 RPM for 21
hours at 2 0C.

The RNA pellet was precipitated in ethanol

and stored at -70C prior to use.
Cytoplasmic RNA was isolated by lysis of cells in an
NP40 buffer.

5 X 107 cells were resuspended in 187 ul of

150 mM NaCl and 10 mM Tris, pH 8.0 containing 5 units of
RNAsin on ice. Lysis was achieved by the addition of 14 ul
of 10% NP-40 and cytoplasmic RNA was isolated in the
supernatant following centrifugation in a microfuge for 1
minute at 4C.

The supernatant was removed into an equal

volume of a urea solution (7M urea; 350mM NaCl; 10 mM Tris,
pH 7.5; 20 mM EDTA; 1% SDS) and extracted twice with phenol:
chloroform (1:1) prior to precipitation with ethanol.
RNA was electrophoresed on 1% agarose gels containing
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IX MOPS (20xnM MOPS; 5xnM NaOAC; lmM EDTA) and 6% formaldehyde
at 200V in a running buffer which contained IX MOPS and 6%
formaldehyde.

RNA was resuspended in IX MOPS, 6%

formaldehyde and 50% formamide and heated at 70C for 10
minutes prior to the addition of gel loading buffer (xylene
cyanol and bromophenol blue in 25% glycerol).

Gels were

transferred to nytran overnight in 2OX SSC following washes
in ddH20; 50mM NaOH and 10 mM NaCl; 0.1M Tris, pH 7.5; and
ddH20 .
rRNA bands were visualized by soaking the filter in 5%
acetic acid and then staining with 0.004% methylene blue in
0.5M NaOAC, pH 5.2 (Davis et al., 1986).
Blots were hybridized according to the method of Church
and Gilbert (1984).

Blots were prehybridized for 3 hours -

overnight at 65C in a sodium phosphate mix (0.5M NaPf, pH
6 .8; 7% SDS; 1% BSA; 0.1 mM EDTA) and denatured probe was
then added directly to the mix for an additional 16-24 hours
at 65C.

Radiolabelling of probes is described in a separate

section.

Blots were washed 3X for 15 minutes at 65C in 40

mM NaPj, 0.5% BSA, 5% SDS, and lmM EDTA.

Two final washes

were carried out in 40 mM NaP,-, 1% SDS and lmM EDTA.
Filters were exposed to Kodak XAR-5 or BB-5 film with
intensifying screens.
Gel Retardation Assays
DNA binding reactions using gel shift mobility assays
were first described by Fried and Crothers (1981).
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The gel

retardation assays performed in this study were modified
from the procedures of Farrell et al. (1989).

Reactions

containing 4 X 10’13M of the appropriate 32P end-labelled
double stranded oligonucleotide and 2 ul of individual trpE
fusion proteins (approximately 100 ng) or 4 ul of a mixture
of two proteins were incubated in 25 microliters of binding
solution (15 mM Hepes, pH 7.9; 75mM KC1; 0.2mM EDTA; lmM
DTT; 7.5% glycerol; 1 ug poly dldC) for 30 minutes at room
temperature or 4C.

Competition assays were conducted with

5, 20 and 50 fold molar excesses of unlabelled competitor
over the 32P labelled MS-AP-1 oligonucleotide.

(The Double

oligonucleotide was used in 2.5, 10 and 25 fold molar
excesses since it contains two potential binding sites
(ZIIIA and ZIIIB)).

The reactions were electrophoresed

under non-dissociating and non-denaturing conditions in 4%
polyacrylamide-0.5X TBE (44 mM Tris-borate, 1 mM borate, 1
mM EDTA) at room temperature or 4C. Gels were then dried on
a Bio-Rad slab gel drying apparatus and autoradiographed.
Gel retardation assays involving casein kinase II were
performed in a 30 ul volume of casein kinase buffer
(described above).

250 ng of purified ZEBRA protein was

incubated at 37C for 15 minutes in the presence of 5 ul of
casein kinase II (purified from bovine testes,Carroll et
al., 1988, 1989) and 1 ul of 10 mM ATP (Pharmacia).

Some

extracts were then subject to treatment with 1 ul protein
phosphatase 2A (PP2A) (10‘5 units) for an additional 15
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minutes at 37C.

PP2A was stored in 50 mM Tris, pH 7.5 and

0.1% BSA and was the kind gift of Jonathan Chernoff.

32P

labelled oligonucleotide probe and 1 ug of poly dldC were
added to each sample and the reactions were incubated for an
additional 30 minutes at 22C.

Samples were then

electrophoresed as described above.
Films from competition experiments were quantified by
densitometer scanning on a Kodak Bioimage densitometer with
Visage 2 000 software.

Disruption of complex formation was

determined by comparing the ratio of shifted complex in
lanes with and without competitor.
Synthetic Oligonucleotides
The synthetic double stranded oligonucleotides used in
binding studies were as follows (sequence reflects top
strand in a 5' to 3' direction):

Core sequences are

underlined and mutated bases are noted in bold type.
MS-AP-1:

TCTTCATGAGTCAGTGCTTC

MS-AP-1*:

TCTTCATTAGTCAGTGCTTC

ZIIIA:

CTAGCTATGCATGAGCCACAGATC

ZIIIA*:

CTAGCTATGCATGAGCAACAGATC

ZIIIAm:

CTAGCTATGCAGAATTCACAGATC

ZIIIB:

CTAGCAGGCATTGCTAATGTACCGATC

ZIIIB*:

CTAGCAGGCATTGCTCATGTACCGATC

ZIIIBm:

CTAGCAGGATCCGCTAATGTACCGATC

Double:

GACTATGCATGAGCCACAGGCATTGCTAATGTACCGA
(contains ZIIIA + ZIIIB)
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Z-AP-1 octamer:

CTAGAAACCATGACATCACAGAGGATC

Control oligo:

TGGCATGCTGCTGACATCTGGC

All oligonucleotides had overhanging Xbal sites at the 5'
end and overhanging BamHI sites at the 3' end, with the
exception of the AP-1 and Double oligonucleotides which had
CT and AG overhangs at the 5' and 3' ends, respectively.
Nitrocellulose DNA-bindinq Assays
Immunoblotting was performed as described above.

Incubation

with radiolabeled DNA (south-westerns) followed the
procedure described by Bowen et al. (1980) and Klempnauer
and Sipper (1987).

Following blocking of immunoblots for 1

hour in Blotto, the blots were washed three times (20
minutes each) with 6M urea; 0.2% NP-40 and four times (30
minutes each) with DNA-binding buffer (10 mM Tris-HCl, pH
7.8; 1 mM EDTA; 50 mM NaCl) at room temperature.

The blots

were incubated with approximately 5 X 106 c.p.m. of nicktranslated 32P-labelled DNA in 10 ml of DNA-binding buffer
for 30 minutes.

Blots were then washed three times (10

minutes each) with DNA-binding buffer prior to analysis by
autoradiography.
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